

CURRICULUM VITAE

David E. Kandzari, MD

**Director, Interventional Cardiology,
Piedmont Heart Institute**

**Chief Scientific Officer,
Piedmont Healthcare**

Atlanta, Georgia

Work Address:

Suite 2065
Piedmont Heart Institute
95 Collier Road
Atlanta, Georgia 30309
Tel : +404 605 5526
Fax : +404 720 0911
Email : david.kandzari@piedmont.org

Current and Prior Appointments

Director, Interventional Cardiology
Director, Interventional Cardiology Research
Piedmont Heart Institute
September 2010-present

Chief Scientific Officer
Piedmont Healthcare
December 2017-present

Chief Scientific Officer
Piedmont Heart Institute
December 2010-2017

Committee Member, Circulatory Systems Devices Panel
United States Food and Drug Administration
March 2009-present; renewed appointment 2015-2019

Medical Officer, Medical Devices Fellowship Program
Center for Devices and Radiological Health, United States Food and Drug Administration
May 2008-January 2009 (Special Government Employee status March 2009-present)

Director, Interventional Cardiology Research
Scripps Clinic, La Jolla, California
August 2008-September 2010

Chief Medical Officer
Cordis Corporation, a Johnson & Johnson Company
December 2006-May 2008

Chief Medical Officer
Conor Medical Systems
March 2007-May 2008

John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences
Assistant Professor of Medicine, Division of Cardiology
Assistant Professor of Molecular Genetics and Microbiology
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
July 2002- December 2006

Education and Training

Duke University School of Medicine, Durham, North Carolina
General and Interventional Cardiology Fellow 1998-2002

The Johns Hopkins University School of Medicine, Baltimore, Maryland
Osler Service Medical Internship and Residency 1995-1998

Duke University School of Medicine, Durham, North Carolina
M.D. 1995 !
Rank: 1/105 !

Duke University, Durham, North Carolina
B.A. Zoology 1991, B.A. Germanic Languages 1991; Magna cum laude

Certification and Licensure

Diplomate, American Board of Internal Medicine, Internal Medicine, 1998

Licensure, State of North Carolina Medical Board 1998-2009; License 99-00559

Licensure, State of Texas Medical Board 2008; License N1357

Licensure, State of California Medical Board 2008; License C53376

Licensure, State of Georgia Medical Board 2010; License 064993

Diplomate, American Board of Internal Medicine, Cardiology Subspecialty, 2003, 2014

Diplomate, American Board of Internal Medicine, Interventional Cardiology Subspecialty, 2005

Refereed Publications

1. ! Burr D, Schaffler M, Yang K, Lukoschek M, Kandzari DE, Sivaneri N, Blaha J, Radin E. Effects of altered strain environments on bone tissue kinetics. *Bone* 1989;10:215-221.
2. ! Heldman AW, Kandzari DE, Tucker RW, Crawford LE, Fearon ER, Koblan KS, Goldschmidt-Clermont PJ. EJ-Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet-derived growth factor-BB via phosphatidylinositol 3-kinase. *Circ Research* 1996;78:312-321.
3. ! Kandzari DE, Warner J, O'Laughlin M, Harrison JK. Percutaneous stenting of right pulmonary artery in fibrosing mediastinitis. *Catheterization and Cardiovasc Intervent* 2000;49:321-4.
4. ! Kandzari DE, Lam LC, Clapp-Channing N, Mark DB, Califf RM, Jollis JG. End-stage coronary artery disease: appropriate endpoints for trials of novel therapies. *Am Heart J* 2001;142:843-851.
5. ! Kandzari DE, Harrison JK, Behar VS. An anomalous left coronary artery originating from the pulmonary artery in a 72-year-old woman: diagnosis by color flow myocardial blush and coronary arteriography. *J Invas Cardiol* 2002;14:96-99.
6. ! Kandzari DE, Roe MT. Integrating GP IIb/IIIa Inhibition into treatment strategies for acute ST-elevation myocardial infarction. *J Invas Cardiol* 2002;14:565-574.
7. ! Kong DF, Hasselblad V, Kandzari DE, Newby KL, Califf RM. Seeking the optimal aspirin dose in acute coronary syndromes. *Am J Cardiol* 2002;90:622-625.
8. ! Kandzari DE, Sketch MH Jr., Goldberg S, et al. for the SCORES Trial Investigators. Clinical outcomes with a self-expanding nitinol stent in saphenous vein grafts: the Stent Comparative REStenosis (SCORES) Registry. *Am Heart J* 2002.
9. ! Kandzari DE, Zidar JP, Behar VS. The VB-1 catheter: a novel catheter for peripheral arterial revascularization. *Cathet Cardiovasc Intervent* 2003;59:514-517.
10. Kong DF, Hasselblad V, Harrington RA, White HD, Tchong JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. *Am J Cardiol* 2003;92:651-655.
11. Kandzari DE. Catheter-based revascularization of the hepatic artery to treat coronary steal from a gastroepiploic artery bypass graft. *J Invas Cardiol* 2003;15:233-236.

12. Kandzari DE, Labinaz M, Cantor WJ, et al. Reduction of Myocardial Ischemic Injury Following Coronary Intervention (the MC-1 to Eliminate Necrosis and Damage Trial). *Am J Cardiol* 2003;92:660-664.
13. Kandzari DE, Tcheng JE, Cohen DJ, et al. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol* 2003;92:779-784.
14. Tcheng JE, Kandzari DE, Grines CL, et al. for the CADILLAC Investigators. Abciximab treatment in primary angioplasty during acute myocardial infarction: final results of the CADILLAC trial. *Circulation* 2003;108:1316-1323.
15. Newby LK, Bhapkar MV, White HD, Moliterno DJ, Allen LaPointe NM, Kandzari DE, Verheugt FWA, Kramer JM, MD, Paul W. Armstrong, MD, Robert M. Califf, MD, for the SYMPHONY and 2nd SYMPHONY Investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding, and discontinuation. *J Thrombosis Thrombolysis* 2003;16:119-128.
16. Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary PCI: results of the LOWTEMP pilot study. *Am J Cardiol* 2004;92:779-784.
17. Kandzari DE, Granger CB, Simoons MS, Califf RM, White HD, Weaver WD, Gore J, Longstreth W, Sime J, Stebbins A, Lee K, Topol EJ for the GUSTO-I Investigators. Risk factors for stroke following thrombolytic therapy: case control study from the GUSTO-I trial. *Am J Cardiol* 2004;93:458-461.
18. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann, FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. *Am Heart J* 2004;147:457-462.
19. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Evidence for enhanced efficacy of discharge aspirin doses ≥ 150 mg after an acute coronary syndrome. *J Am Coll Cardiol* 2004;43:972-978.
20. Kandzari DE, Tcheng, JE, Grines CL, et al. Influence of admission and discharge aspirin use on survival after primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2004;94:1029-1033.
21. Kandzari DE, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Schömig A, Kastrati A, Berger PB, for the Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. Influence of treatment duration with a 600 mg dose of clopidogrel prior to percutaneous coronary revascularization. *J Am Coll Cardiol* 2004;44:2133-2166.
22. Kandzari DE, Roe MT, Chen AY, Lytle B, Pollack CV, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Influence of clinical trial enrollment on the quality

- of care and outcomes for patients with non–ST-segment elevation acute !
coronary syndromes. *Am Heart J* 2005;149:474-481. !
23. Waters RE, Kandzari DE, Phillips HR, Crawford LE, Sketch MH. Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. *Cathet Cardiovasc Intervent* 2005;65:520-524.
 24. Halabi AR, Kandzari DE. The thrill is gone: catheter-based exclusion of a posttraumatic arteriovenous fistula with a covered stent graft. *Cathet Cardiovasc Intervent* 2005;66:27-33.
 25. Sorajja P, Gersh BJ, MB, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, MD, Garcia E, Tchong JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Relative prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. *Eur Heart J* 2005;26:667-674.
 26. Kandzari DE, Roe MT, Milford-Beland S, Ohman EM, Chen AY, Lytle BL, Cohen DJ, Smith SC, Harrington RA, Gibler WB, Peterson ED. Frequency, patterns and predictors of drug eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE quality improvement initiative. *Am J Cardiol* 2005;96:750-755.
 27. Stone GW, Colombo A, Teirstein PS, Moses JW, Leon MB, Reifart NJ, Mintz GS, Hoyer A, Cox DA, Baim DS, Strauss BH, Selmon M, Moussa I, Suzuki T, Tamai H, Katoh O, Mitsudo K, Grube E, Cannon LA, Kandzari, DE, Reisman M, Schwartz RS, Bailey S, Dangas G, Mehran R, Abizaid A, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. *Cathet Cardiovasc Intervent* 2005;66:217-236.
 28. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz R, Bailey S, Moussa I, Teirstein PS, Dangas G, Baim DS, Selmon M, Strauss B, Tamai H, Suzuki T, Mitsudo K, Katoh O, Cox DA, Hoyer A, Mintz GS, Grube E, Cannon L, Reifart NJ, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: Part I. *Circulation* 2005;112:2364-2372.
 29. Stone GW, Reifart NJ, Moussa I, Hoyer A, Cox DA, Colombo A, Baim DS, Teirstein PS, Strauss BH, Selmon M, Mintz GS, Katoh O, Mitsudo K, Suzuki T, Tamai H, Grube E, Cannon L, Kandzari DE, Reisman M, Schwartz R, Bailey S, Dangas G, Mehran R, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: Part II. *Circulation* 2005;112:2530-2537.
 30. Kandzari DE, Tchong JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, Stone GW, for the CADILLAC Investigators. Relationship between infarct artery location, epicardial flow, and myocardial perfusion following primary percutaneous revascularization in acute myocardial infarction *Am Heart J* 2006;

31. Kandzari DE, Kiesz RS, Allie D, Walker C, Fail P, Ramaiah VG, Cardenas J, Vale J, Chopra A, Gammon RG. Procedural and clinical outcomes for a novel method of catheter-based plaque excision in critical limb ischemia. *J Endovasc Ther* 2006;13:12-22.
32. Kandzari DE, Tuttle RH, Zidar JP, Jollis JG. Influence of stenting on long-term outcomes among patients undergoing percutaneous coronary revascularization in clinical practice: 7-year follow-up from the Duke Database for Cardiovascular Disease *Am J Cardiol* 2006;97:1467-1472.
33. Patel MR, Albert TSE, Kandzari DE, Honeycutt E, Shaw LK, Sketch MH, Elliott M, Judd R, Kim RJ. Clinical outcomes following cardiac magnetic resonance imaging early after percutaneous revascularization for acute myocardial infarction with drug-eluting and bare metal stents. *Radiology* 2006;240:674-680.
34. Kandzari DE, Tuttle RH, Zidar JP, Jollis JG. Temporal Trends in Target Vessel Revascularization in Clinical Practice: Long-term Outcomes Following Coronary Stenting from the Duke Database for Cardiovascular Disease. *J Invas Cardiol* 2006;18:398-402.
35. Rao S, Honeycutt E, Kandzari DE. Clinical outcomes with drug-eluting stents following atheroablation therapies. *J Invas Cardiol* 2006;18:393-396.
36. Eisenstein E, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term outcomes after drug-eluting stent implantation. *JAMA* 2007;10;297:159-168.
37. Kandzari DE, Leon MB, Popma JJ, et al. for the ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. *J Am Coll Cardiol* 2006;48:2440-2447.
38. Ramaiah V, Gammon R, Kiesz S, Cardenas J, Runyon JP, Fail P, Walker C, Allie DE, Chamberlin J, Solis M, Garcia L, Kandzari D; TALON Registry. Midterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection. *J Endovasc Ther.* 2006;13:592-602.
39. Ikeno F, Braden GA, Kineda H, Hongo Y, Hinohara T, Yeung AC, Simpson JB, Kandzari DE. Mechanism of luminal gain with plaque excision in atherosclerotic coronary and peripheral arteries: assesment by histology and intravascular ultrasound. *J Interven Cardiol* 2007;20:107-113.
40. Tardif JC, Carrier M, Kandzari DE, Emery R, Cote R, Heinonen T, Zettler M, Hasselblad V, Guertin MC, Harrington RA. Effects of pyridoxal-5-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery. Results of the MEND-CABG randomized study. *J Thorac Cardiovasc Surg* 2007;133:1604-1611.

41. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. *Am Heart J*. 2007 May;153(5):874-80.
42. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, Resnic F, Yakubov S, Callahan K, Borgman M, Cohen SA. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenosis: results of a multi-center 350-patient case control study. *J Invas Cardiol* 2007;19:404-409.
43. Miyazawa A, Ako A, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AHM, Kandzari DE, Honda Y, Fitzgerald PJ, for the ENDEAVOR III Investigators. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. *Am Heart J* 2007;155:108-113.
44. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate endpoints in drug-eluting stent trials: a systematic evaluation based on individual patient data from eleven randomized controlled trials. *J Am Coll Cardiol* 2008;51:23-32.
45. Menon V, Chen AY, Roe MT, Kandzari DE, Cohen MG, Gibler WB, Smith SC, Ohman EM. Incidence, Outcome and Predictors of Cardiogenic Shock Complicating Non-ST-segment Elevation Acute Coronary Syndromes: Findings from CRUSADE. *In Press*
46. Carrier M, Emery R, Kandzari DE, Harrington R, Guertin MC, Tardif JC. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial. *J Cardiovasc Surg* 2008;49(2):249-253.
47. Mayor M, Kandzari DE, Malik AZ, Minor R, Deshpande M, Strauss WE, Maloney TH, Baim DS, O'Neill W. One-year outcomes in diabetic patients from the TAXUS Express² stent vs Cypher stent: What's Your Real-World Experience? (TC-WYRE) Registry. *Am J Cardiol* 2009;103:930-936.
48. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE, Barajas O, Leon MB. Stent fracture late following sirolimus-eluting stent implantation: a qualitative and quantitative angiographic analysis. *Am J Cardiol* 2009;103:923-929.
49. Price MP, Teirstein PS, Berger PB, Tanguay JF, Angiolillo D, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized anti-platelet therapy after drug eluting stent implantation in patients with high residual platelet reactivity on clopidogrel: design and rationale of the GRAVITAS trial. *Am Heart J* 2009;157:818-824.
50. Kandzari DE, Rao S, Moses JW, Dzavik V, Strauss B, Kutryk MJ, Simonton CA, Garg J, Likhnygna, Mancini GBJ, Yeoh E, Buller CE for the ACROSS/TOSCA-4

- Investigators. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: ACROSS/TOSCA-4 trial. *J Am Coll Cardiol Interv* 2009;2:97-106.
51. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. *Am J Cardio* 2009;103:1339-1343.
 52. Wang TY, Samad Z, Barnhart HX, Huang Z, Hurwitz LM, Heyneman LE, Ryan KA, Raman SV, Emlein G, Earls J, Kandzari DE. Use of multi-row detector computed tomography for the assessment and treatment of coronary stenosis: the Comparison of Noninvasive CT Angiography for Epicardial Coronary Imaging with Catheter-based Angiography (CINEMA) Study. *Submitted*
 53. Leon MB, Kandzari DE, Eisenstein E, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Popma JJ, for the ENDEAVOR IV Investigators. Late safety, efficacy, and cost effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with *de novo* coronary lesions: two-year follow-up from the ENDEAVOR IV trial. *J Am Coll Cardiol Interv* 2009;2:1208-1218.
 54. Rao S, Cohen MG, Kandzari DE, Bertrand O, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. *J Am Coll Cardiol* 2010;55:2187-2195.
 55. Mauri L, Massaro JM, Jiang ST, Meredith I, Wijns W, Fajadet J, Kandzari DE, Leon MB, Cutlip DE, Thompson KP. Long-term clinical outcomes with zotarolimus-eluting coronary stents: five-year results of the pooled ENDEAVOR trials. *Submitted*
 56. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJ. Intravascular ultrasound results from the ENDEAVOR IV trial: comparison between zotarolimus-eluting stent and paclitaxel-eluting stent. *J Am Coll Cardiol Interv* 2009;2:779-784.
 57. Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. *J Am Coll Cardiol Interv* 2009;2:967-76.
 58. Kandzari DE, Colombo A, Park SJ, Tommaso CL, Ellis SG, !Guzman LA, Teirstein PS, Tamburino C, Ormiston J, Stone GW, MD, Dangas GD, Popma JJ, Bass TA, on behalf of the American College of Cardiology Interventional Scientific Council. Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards. *J Am Coll Cardiol* 2009;54:1576-1588.

59. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the Cypher sirolimus-eluting stent: three-year results from the ENDEAVOR III trial. *J Am Coll Cardiol Interv* 2009; 2:1199-1207.
60. Nayak KR, Mehta HS, Price MJ, Russo RJ, Stinis CT, Moses JW, Mehran R, Leon MB, Kandzari DE, Teirstein PS. A novel technique for ultra-low contrast administration during angiography or intervention. *Cathet Cardiovasc Intervent* 2010;75:1076-1083.
61. Lee MD, Yang T, Kandzari DE, Tobis JM, Liao H, Mahmud E. Comparison by meta-analysis of drug-eluting stents with bare metal stents for saphenous vein graft intervention. *Am J Cardiol* 2010;105:1076-1082.
62. Kandzari DE, Farb A, Boam AB. Percutaneous Coronary Intervention in Perspective: Drug-Eluting Stents as a Model for Regulatory Review. *Circ Cardiovasc Intervent* 2009;2:574-579.
63. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen B, MD, Kirtane A, Fitzgerald PJ, Kandzari DE, for the ENDEAVOR IV Investigators. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in *de novo* native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. *J Am Coll Cardiol* 2010;55:543-554.
64. Brown RA, Williams M, Barker CM, Mauri L, Meredith IT, Fajadet J, Wijns W, Leon MB, Kandzari DE. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results. *Cathet Cardiovasc Intervent* 2010
65. Yang Y, Kandzari DE, Gao Z, Xu B, Chen J, Qiao S, Li J, Qin X, Yao M, Wu Y, Yuan J, Chen J, Liu H, Dai J, Chen T, Li W, Gao R. Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. *J Am Coll Cardiol Intv* 2010;3:1045-1042.
66. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 polymorphism status in patients with high on-treatment reactivity. *J Am Coll Cardiol Intv* 2010;3:1001-1007.
67. Kandzari DE, Zankar A, Teirstein PS, Brilakis E, Banerjee S, Price M, Stinis C, Hudson P, Dahle T, Eng M, Brown R, Ferguson A, Addo TA, Popma JJ. Clinical outcomes following predilation with a novel 1.25 mm diameter angioplasty catheter. *Cathet Cardiovasc Intervent* 2011;77:510-514.
68. Saeed B, Kandzari DE, Agostoni P, Lombardi WL, Rangan BV, Banerjee S, Brilakis ES. Use of drug-eluting stents for chronic total occlusions: a systematic review and meta- analysis. *Cathet Cardiovasc Intervent* 2011;77:315-332.

69. Lee MS, Bokhoor P, Park SJ, Kim YH, Stone GW, Sheiban I, Biondi-Zoccai G, Sillano D, Tobis J, Kandzari DE. Unprotected left main coronary disease and acute myocardial infarction: a contemporary review and argument for percutaneous coronary intervention. *J Am Coll Cardiol Interv* 2010;3:791-795.
70. Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE, for the ENDEAVOR IV Investigators. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with *de novo* coronary lesions: three-year follow-up from the randomized ENDEAVOR IV trial. *J Am Coll Cardiol Interv* 2010;3:1043-1050.
71. Mauri L, Massaro JM, Jiang S, Meredith I, Wijns W, Fajadet J, Kandzari DE, Leon MB, Cutlip DE, Thompson KP. Long-term clinical outcomes with zotarolimus-eluting coronary stents versus bare metal coronary stents. *J Am Coll Cardiol Interv* 2010;3:1240-1249.
72. Ormiston JA, Devroey F, Webster MWI, Kandzari DE. The Petal Dedicated Bifurcation Stent. *Eurointervention* 2010. *Eurointervention* 2010;6.
73. Lee MS, Stone GW, Park SJ, Teirstein PS, Moses JW, Colombo A, Kandzari DE. Percutaneous coronary intervention of unprotected left main coronary artery disease: procedural strategies and technical considerations. *Cathet Cardiovasc Intervent* *In press*; July 25 2011 DOI:1002/ccd.22689.
74. Erlinge D, Gotberg M, Grines C, Dixon S, Baran K, Kandzari DE, Olivecrona GK. A pooled analysis of the effect of endovascular cooling on infarct size in patients with ST-elevation myocardial infarction. *EuroIntervention*. 2012 Nov 20. doi:pil: 20110718-02.
75. Lee MS, Yang T, Kandzari DE, Mahmud E, Liao H, Kirtane A. Late-term outcomes in patients treated with drug-eluting and bare metal stents for treatment of transplant coronary artery disease. *Cathet Cardiovasc Intervent* 2012;80:533-538.
76. Price MJ, Berger PB, Teirstein PS, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, for the GRAVITAS Investigators. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial. *JAMA* 2011;305:1097-1105.
77. Lee MS, Park SJ, Kandzari DE, Kirtane A, Fearon W, Brilakis E, Vermeersch P, Kim, YH, Waksman R, Mehilla J, Mauri L, Stone GW. Saphenous vein graft intervention. State of the art 2011. *J Am Coll Cardiol Interv* 2011;4:831-843.
78. Kandzari DE, Barker CS, Leon MB, Mehran R. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. *J Am Coll Cardiol Interv* 2011;4:1119-1128.
79. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-

- Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). *J Am Coll Cardiol Interv* 2011;4:543-550.
80. Karpaliotis D, Lembo N, Kalynych A, Carlson H, Lombardi WL, Anderson C, Rinehart S, Kirkland B, Chambless PA, Shemwell K, Qian Z, Voros S, Kandzari DE. Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical and cost-utilization outcomes. *Catheter Cardiovasc Interv* 2013 Apr 11. doi: 10.1002/ccd.24387.
 81. Kandzari DE, Ormiston JA. Revascularization for Unprotected Left Main Coronary Artery Disease: An Evolution in Clinical Decision Making. *Curr Cardiol Reports* 2011;13:424-431.
 82. Vavalle JP, Stevens SR, MS, Hassinger N, Cohen MG, Arnold A, Kandzari DE, Aguirre FV, MD, Gretler DD, Alexander JH. The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. *Am Heart J* 2011; 162:996-1002.
 83. Kandzari, DE. Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. *Future Medicine* 2012;4:147-150.
 84. Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IA, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD, Stone GW. Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomized controlled clinical trials. *Eurointervention* 2012; published online ahead of print March 25, 2012.
 85. Lee MS, Cheng R, Kandzari DE, Kirtane A. Long-term outcomes of heart transplantation recipients with transplant coronary artery disease who develop in-stent restenosis after percutaneous coronary Intervention. *Am J Cardiol* 2012;109:1729-1732.
 86. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack J, MD, Katzen Leon MB, Massaro J, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend R, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPPLICITY Hypertension-3 Trial. *Clinical Cardiology* 2012. Published online ahead of print May 9 2012, DOI: 10.1002/clc.22008.
 87. Karpaliotis D, Lembo NJ, Brilakis ES, Kandzari DE. Percutaneous chronic total occlusion revascularization: program development, resource utilization and economic outcomes. *Intervent Cardiol Clin* 2012;1:391-395.
 88. Karpaliotis D, Michael T, Brilakis ES, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi WL, Kandzari DE. Retrograde coronary chronic total occlusion revascularization: procedural and in-hospital outcomes from a

- multicenter registry in the United States. *Cathet Cardiovasc Intervent* 2012. *In press*
89. Brilakis ES, Grantham JA, Rinfret S, Wyman RM, Burke NM, Karpaliotis D, Lembo N, Pershad A, Kandzari DE, Buller CE, DeMartini T, Lombardi WL, Thompson CA. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. *J Am Coll Cardiol Interv* 2012;5:367-379.
 90. Karpaliotis, D, Michael T, Brilakis ES, Lembo NJ, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Retrograde Coronary Chronic Total Occlusion Revascularization: Procedural and In-Hospital Procedural Outcomes from a Multicenter Registry in the United States. *J Am Coll Cardiol Interv* 2012;5:1273-1279.
 91. Rogers JH, Goldstein I, Kandzari DE, Köhler T, Stinis C, O'Connell K, Foss J, Woodson Z, Dolan M, Rocha-Singh K. Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors. *J Am Coll Cardiol* 2012;60:2618-2627.
 92. Kosmidou I, Dan D, Karpaliotis D, Kandzari DE. Inadvertent Transarterial Lead Placement in the Left Ventricle and Aortic Cusp: Percutaneous Extraction with Carotid Embolic Protection and Stent Graft Placement. *Indian Pacing Electrophysiol J.* 2012;12(6):269-273.
 93. Bagur R, Bernier M, Kandzari DE, Karpaliotis D, Lembo NJ, Rinfret S. A Novel Application of Contrast Echocardiography to Exclude Active Coronary Perforation Bleeding in Patients With Pericardial Effusion. *Cathet Cardiovasc Intervent* 2013;82:221-229.
 94. Gao Z, Xu B, Yang YJ, Kandzari DE, Yan HB, Chen JL, Qiao SB, Wu YJ, Qin XW, Yao M, Yuan JQ, Liu HB, Chen J, Dai J, Chen T, Teng SY, Gao RL. Clinical and angiographic correlates of left ventricular dysfunction in patients with three vessel coronary disease. *Chin Med J* 2012;125:4221-4225.
 95. Park KW, MD, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van Boven AJ, MD, Hofma SH, Kang HJ, MD, Koo BK, Oh BH, Park YB, Kandzari DE, Kim HS. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a meta-analysis of 11 randomized controlled trials and 3 observational studies. *Am Heart J* 2013;165(2):241-250.
 96. Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L. Final 5-Year Outcomes from the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program: Comparison of Safety and Efficacy with First Generation Drug-Eluting and Bare Metal Stents. *J Am Coll Cardiol Interv* 2013;6:504-512.
 97. Kirtane A, Leon MB, Kandzari DE. The "final" five-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. *JACC Cardiovasc Interv.* *J Am Coll Cardiol Interv.* 2013;6:325-333.
 98. Kandzari DE, Teirstein PS, Kereiakes D, Cannon LA, Heame SE, Kuo HC, Ying

- SW, Cheong WF, Popma JJ. Procedural Effectiveness of a Novel 1.20 mm Diameter Angioplasty Catheter: Clinical and Angiographic Outcomes. *Interv Cardiol*. 2013 Apr;26(2):131-136.
99. Karpaliotis D, Michael TT, Brilakis ES, Fuh E, Mogabgab PV, Kirkland BL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Coronary chronic total occlusion revascularization: procedural outcomes from a multicenter United States registry. *Am J Cardiol* 2013;112:488-492.
100. ! Vardi M, Burke DA, Bangalore S, Pencina MJ, Mauri L, Kandzari DE, Leon MB, Cutlip DE. Long Term Efficacy and Safety of Zotarolimus Eluting Stent in Patients with Diabetes Mellitus: Pooled 5-year Results of the ENDEAVOR III and IV Trials. *Circ Cardiovascular Intervent* 2013;82:1031-1038.
101. ! Park KW, Kang J, Kang SH, Ahn HS, Lee HY, Kang HJ, Koo BK, Chae IH, Youn TJ, Oh BH, Park YB, Kandzari DE, Kim HS. Usefulness of the SYNTAX and Clinical SYNTAX Scores in Predicting Clinical Outcome After Unrestricted Use of Sirolimus-and Everolimus-Eluting Stents. *Circ J*. 2013;77(12):2912-21.
102. ! Yu M, Xu B, Wu Y, Yan H, Chen J, Qian J, Mu C, Hu F, Yang W, Qiao S, Yang Y, Kandzari DE, Gao RL. First Report of a Novel Polymer-Free Dual-Drug Eluting Stent in *De Novo* Coronary Artery Disease: Results of the First in Human BICARE Trial. *Cathet Cardiovasc Intervent* 2013;DOI: 10.1002/ccd.25129
103. ! Navarese EP, Tandjug K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes D, Waksman R, Mauri L, Meridith I, Fin A, Kubica J, Di Pasquale G, Von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. *BMJ* 2013;347:f6530. doi: 10.1136/bmj.f6530.
104. ! Ormiston J, Webster, MB, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With *De Novo* Lesion in the Native Coronary Arteries). *J Am Coll Cardiol Intv* 2013 doi.org/10/1016/j.jcin.2013.05.013
105. ! Park KW, Kang J, Kang SH, Ahn HS, Kang HJ, Koo BK, Chae IH, MD, Youn TJ, Oh BH, Park YB, Kandzari DE, Kim HS. The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: residual SYNTAX score after PCI in patients from the EXCELLENT registry. *Am Heart J* 2014;167:384-392.
106. ! Michael TT, Karpaliotis D, Brilakis ES, Abdullah SM, Kirkland BL, Mishoe KL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry. *Heart*. 2013;99(20):1515-1518.

107. ! Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. *Lancet*. 2013 Aug 30. doi:pii: S0140-6736(13)61782-1.
108. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable-polymer drug-eluting stents versus bare metal stents versus durable-polymer drug-eluting stents. A systematic review and Bayesian approach network meta-analysis. *Eur HeartJ* 2014; doi:10.1093/eurheartj/eh570.
109. ! Howard JP, Cole GD, Sievert H, Bhatt D, Papademetriou V, Kandzari DE, Davies JE, Francis DP. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. *Int J Cardiol* 2014;172:29-35.
110. ! Michael TT, Karpaliotis D, Brilakis ES, Alomar M, Abdullah SM, Kirkland BL, Mishoe KL, Lembo N, Kalynych A, Carlson H, Banerjee S, Luna M, Lombardi W, Kandzari DE. Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: Insights from a multicenter United States registry. *Catheter Cardiovasc Interv* 2014;doi: 10.1002/ccd.25359.
111. ! Michael TT, Karpaliotis D, Brilakis ES, Fuh E, Patel VG, Mogabgab O, Alomar M, Kirkland BL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Procedural outcomes of revascularization of chronic total occlusion of native coronary arteries (from a multicenter United States registry). *Am J Cardiol* 2013;112:488-492.
112. ! Michael TT, Karpaliotis D, Brilakis ES, Abdullah SA, Kirkland BL, Mishoe KL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi WL, Kandzari DE. Impact of Prior Coronary Artery Bypass Graft Surgery on Chronic Total Occlusion Revascularization: Insights from a Multicenter US Registry. *Heart* 2013;99:1515-1518.
113. ! Navarese EP, Kowalewski M, Cortese B, Kandzari D, Dias S, Wojakowski W, Buffon A, Lansky A, Angelini P, Torguson R, Kubica J, Kelm M, Jan de Boer M, Waksman R, Suryapranata H. Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. *Atherosclerosis* 2014;233:224-231.
114. ! Gao Z, Xu B, Yang Y, Kandzari DE, Sun Y, Qiao S, Wu Y, Yan H, Yuan J, Chen J, Shao Y, Gao R. Transradial versus transfemoral method of two-stent implantation for true bifurcation lesions: comparison of immediate and long-term outcomes. *J Intervent Cardiol* 2014;9999:1-9.
115. ! Christopoulos G, Karpaliotis D, Alaswad K, Lombardi W, Grantham A, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy of "hybrid"

- percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: Insights from a US multicenter registry. *Catheter Cardiovasc Interv*. 2014 doi: 10.1002/ccd.25465.
116. ! Christopoulos G, Karpaliotis D, Alaswad K, Lombardi W, Grantham A, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. Application of the "hybrid Approach" to chronic total occlusions in patients with prior coronary artery bypass surgery (from a contemporary multicenter US registry. *Am J Cardiol* 2014;113:1990-1994.
117. ! Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL for the SYMPLICITY HTN-3 Investigators. A randomized, controlled trial of renal denervation for resistant hypertension. *N Engl J Med* 2014; 10.1056/NEJMoa1402670
118. ! Pancholy SB, ShanthavG, Patel TM, Sobotka PA, Kandzari DE. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. *Am J Cardiol* 2014;114:856-861.
119. ! Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. *J Am Coll Cardiol* 2014 doi: 10.1016/j.jacc.2014.05.012
120. ! Galassi A, Grantham A, Kandzari D, Lombardi W, Moussa I, Thompson C, Werner G, Chambers C, Brilakis E. Percutaneous treatment of coronary chronic total occlusions part 1: rationale and outcomes. *Interventional Cardiology Review* 2014;9(3):201-208.
121. ! Christopoulos G, Menon RV, Karpaliotis D, Alaswad K, Lombardi W, Grantham A, Patel VG, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy and safety of the "hybrid" approach to coronary chronic total occlusions: insights from a contemporary multicenter US registry and comparison with prior studies. *J Invasive Cardiol*. 2014;26:427-432.
122. ! Galassi A, Grantham A, Kandzari D, Lombardi W, Moussa I, Thompson C, Werner G, Chambers C, Brilakis E. Percutaneous treatment of coronary chronic total occlusions part 2: technical approach. *Interventional Cardiology Review* 2014;9(3):208-213.
123. ! Foran JP, Jain AK, Casserly I, Kandzari DE, Rocha-Singh KJ, Witkowski A, Katzen BT, Deaton D, Balmforth P, Sobotka PA. The ROX Coupler: creation of a fixed ilio-femoral arteriovenous anastomosis for the treatment of systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. *Cathet Cardiovasc Intervent* 2015;85:880-886.

124. ! Carlino M, Magri CM, Uretsky BF, Brilakis ES, Walsh S, Spratt JC, Hanratty C, Grantham JA, Rinfret S, Thompson CA, Lombardi WL, Galassi AR, Sianos G, Latib A, Garbo R, Karpaliotis D, Kandzari DE, Colombo A. Treatment of the chronic total occlusion: a call for action to the interventional community. *Cathet Cardiovasc Intervent* 2015;85:771-778.
125. ! Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Normand SLT, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L, on behalf of the Dual Antiplatelet Therapy (DAPT) Study Investigators. Drug-eluting versus bare metal stents in patients receiving dual antiplatelet therapy. *JAMA* 2015;313:1113-1121.
126. ! Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SLT, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman H, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, on behalf of the Dual Antiplatelet Therapy (DAPT) Study Investigators. Dual antiplatelet therapy beyond one year after drug-eluting coronary stent procedures. *N Engl J Med* 2014
127. ! Navarese EP, Shulze V, Kowalewski M, Andreotti A, Kołodziejczak M, Kandzari DE, Rassaf T, Bartosz Gorny G, Brockmeyer M, Meyer C, Berti S, Kubica J, Kelm M, Valgimigli M. Comprehensive meta-analysis of safety and efficacy of bivalirudin vs heparin with or without GPIIb/IIIa inhibitor in patients with acute coronary syndrome. *JACC Cardiovasc Interv.* 2015 Jan;8(1 Pt B):201-13. doi: 10.1016/j.jcin.2014.10.003. Epub 2014 Nov 1
128. ! Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. *Eur Heart J* 2014
129. ! Kandzari DE, Kini AS, Karpaliotis D, Moses JW, Tummala PE, Grantham JA, Orr C, Lombardi W, Nicholson WJ, Lembo NJ, Popma JJ, Wang J, Larracas C, Rutledge DR. Safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: results from the Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Occusions (EXPERT CTO) Multicenter Trial. *J Am Coll Cardiol Intv* 2015;doi.10.1016/j.jcin.2014.12.238
130. ! Alaswad K, Menon RV, Christopoulos G, Lombardi WL, Karpaliotis D, Grantham JA, Marso SP, Wyman MR, Pokala NR, Patel SM, Kotsia AP, Rangan BV, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia SA, Thompson CA, Banerjee S, Brilakis ES. Transradial Approach for Coronary Chronic Total Occlusion Interventions: Insights from a Contemporary Multicenter Registry. *Cathet Cardiovasc Intervent* 2015 DOI: 10.1002/ccd.25827.
131. ! Christopoulos G, Karpaliotis D, Wyman MR, Alaswad K, McCabe J, Lombardi WL, Grantham JA, Marso SP, Kotsia AP, Rangan BV, Garcia SA,

- Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Thompson CA, Banerjee S, Brilakis ES. Percutaneous Intervention of Circumflex Chronic Total Occlusions Is Associated With Worse Procedural Outcomes: Insights From a Multicentre US Registry. *Can J Cardiol*. 2014 Dec;30(12):1588-94. doi: 10.1016/j.cjca.2014.07.007.
132. ! Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górný B, Kołtowski L, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. *Open Heart*. 2014 Aug 21;1(1):e000064. doi: 10.1136/openhrt-2014-000064.
133. ! Navarese EP, Kołodziejczak M, Schulze V, Gurbel PA, Tantry U⁴, Lin Y, Maximilian Brockmeyer M, Kandzari DE, Kubica JM, ⁶, D'Agostino RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of PCSK9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. *Annals Int Med* 2015 doi:10.7326/M14-2957.
134. ! White WB, Galis ZS, Henegar J, Kandzari DE, Victor R, Sica D, Townsend RR, Turner JR, Virmani R, Mauri L. Renal denervation therapy for hypertension: pathways for moving development forward. *J Am Soc Hypertens*. 2015;9:341-350.
135. ! Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. Renal denervation for the treatment of hypertension: making a new start, getting it right. *J Clin Hypertens* 2015 May 14. doi: 10.1111/jch.12590.
136. ! Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. Renal denervation for the treatment of hypertension: making a new start, getting it right. *Catheter Cardiovasc Interv* 2015 June 11. doi: 10.1002/ccd.26028.
137. ! Giustino G, MD, Baber U, Stefanini GG, Stone GW, Aquino M, Sartori S, Leon, Windecker S, Serruys PW, Morice MC, Wijns W, Camenzind E, Weisz G, Steg PG, Smits PC, Kandzari DE, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia G, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Impact of Clinical Presentation (Stable Angina Pectoris Versus Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction versus ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. *Am J Cardiol* 2015
138. ! Christopoulos G, Wyman RM, Alaswad K, Karpaliotis, Lombardi W, Grantham JA, Yeh RW, Jaffer FA, Cipher DJ, Rangan BV, Christakopoulos GE, Kypreos M, Lembo N, Kandzari D, Garcia S, Thompson CA, Banerjee S, Brilakis ES. Clinical utility of the Japan–Chronic Total Occlusion Score in coronary chronic total occlusion interventions: results from a multicenter registry. *Circ Cardiovasc Interv*. 2015;8:e002171. doi: 10.1161/CIRCINTERVENTIONS.114.002171.

139. ! Flack J, Bhatt D, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in SYMPPLICITY HTN-3 trial. *J Am Soc Hypertens* 2015;9:769-779.
140. ! Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Liu M, Linz D, Davies J, Kandzari DE, Whitbourn R, Böhm M, Melder RJ. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation: the IVY approach. *J Am Coll Cardiol* 2015;66:1766-1775.
141. ! Giustino G, Baber U, Salianski O, Sartori S, Stone G, Leon MB, Aquino M, Stefanini G, Steg PG, Windecker S, O'Donoghue M, Wijns W, Serruys P, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits P, Kandzari D, von Birgelen C, Dangas G, Cha JY, Galatius S, Jeger R, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of new-generation drug-eluting stents in women at high-risk for atherothrombosis: from the women in innovation and drug-eluting stents (WIN-DES) collaborative patient-level pooled analysis. *Circ Cardiovasc Intervent* 2015.
142. ! Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; DAPT Study Investigators. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. *JACC Cardiovasc Interv.* 2015 Oct;8(12):1552-1562. doi: 10.1016/j.jcin.2015.05.026.
143. ! Christopoulos G, Karpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman RM, Lombardi WL, Menon RV, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh M, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Tarar MN, Christakopoulos GE, Thompson CA, Banerjee S, Brilakis ES. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. *Int J Cardiol.* 2015 Nov 1;198:222-8. doi: 10.1016/j.ijcard.2015.06.093.
144. ! Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Townsend R, Weber MA, Bohm M. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. *Am Heart J* 2016;171:82-91.
145. ! Kandzari DE, Amjadi N, Caputo C, Rowe SK, Williams J, Tamboli HP, Christen T, Allocco DJ, Dawkins KD. One-year outcomes in "real-world" patients treated with a thin-strut, platinum-chromium, everolimus-eluting stent from the PROMUS Element Plus US Post-Approval Study (PE-Plus PAS), *Am J Cardiol* 2016;117:539-545.
146. ! Giustino G, Baber U, Genereux P, Sartori S, Chandrasekhar J, Stone GW, Leon MB, Salianski O, Dangas GD, Aquino M, Stefanini GG, Steg PG,

- Windecker S, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Saporito R, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of new-generation drug-eluting stents in women undergoing complex percutaneous coronary revascularization: from the Women in Innovation and Drug-Eluting Stents (WIN-DES) collaborative patient-level pooled analysis. *J Am Coll Cardiol Interv* 2016;9:674-684.
147. ! Damluji A, Pomenti SF, Ramireddy A, Al-Damluji MS, Alfonso CE, Schob AH, Marso SP, Gilchrist IC, Moscucci M, Kandzari DE, Cohen MG. Influence of total coronary occlusion on clinical outcomes (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). *Am J Cardiol* 2016 *In press*
148. ! Baber U, Giustino G, Salianski O, Sartori S, Stone G, Leon MB, Aquino M, Stefanini G, Steg PG, Windecker S, O'Donoghue M, Wijns W, Serruys P, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits P, Kandzari D, von Birgelen C, Dangas G, Cha JY, Galatius S, Jeger R, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Effect of chronic kidney disease in women undergoing percutaneous coronary intervention with drug-eluting stents: a patient-level pooled analysis of randomized controlled trials. *J Am Coll Cardiol Interv* 2016;11:28-38.
149. ! Christopoulos G, Kandzari DE, Yeh RW, Jaffer FA, Karpaliotis D, Wyman MR, Alaswad K, Lombardi W, Grantham JA, Moses J, Christakopoulos G, Tarar MN, Rangan BV, Lembo N, Garcia S, Cipher D, Thompson CA, Banerjee S, Brilakis ES. Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score. *JACC Cardiovasc Interv.* 2016;11:1--9.
150. ! Biasco L, Gotberg M, Harnek J, Lundin A, Kandzari DE, De Backer O, Olivecrona GK. First-in-man experience with the ClearLumen thrombectomy system as an adjunctive therapy in primary percutaneous coronary interventions. *J Interv Cardiol* 2016;29:155-161.
151. ! Kandzari DE, Perumal R, Bhatt DL. Frequency and implications of ischemia prior to ventricular tachyarrhythmia in patients treated with a wearable cardioverter defibrillator following myocardial infarction. *Clin Cardiol* 2016;39:399-405.
152. ! Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend RR, Bakris G. Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension. Insights from the SYMPPLICITY HTN 3 Trial. *Circulation J* 2016. <http://doi.org/10.1253/circj.CJ-16-0035>.
153. ! Danek BA, Karatasakis A, Karpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Patel M, Bahadorani J, Lombardi WL, Wyman MR, Grantham JA, Doing A,

- Moses JW, Kirtane A, Parikh M, Ali ZA, Kalra S, Kandzari DE, Lembo N, Garcia S, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. *Int J Cardiol.* 2016;214:428-437.
154. ! Giustino G, Baber U, Salianski O, Sartori S, Stone GW, Leon MB, Aquino M, Stefanini GG, Steg PG, Windecker S, O' Donoghue M, Wijns W, Serruys PW, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Dangas GD, Cha JY, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Genereux P, Chieffo A, Mehran R. Safety and efficacy of new-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis: From the women in innovation and drug-eluting stents collaborative patient-level pooled analysis. *Circ Cardiovasc Interv.* 2016 Jan;9(1):e002995. doi: 10.1161/CIRCINTERVENTIONS.115.002995.
155. ! Karacsonyi J, Karatasakis A, Karpalotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman MR, Lombardi WL, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh MA, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Martinez Parachini JR, Resendes E, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. Effect of previous failure on subsequent procedural outcomes of chronic total occlusion percutaneous coronary intervention (from a contemporary multicenter registry). *Am J Cardiol.* 2016;117:1267-1271.
156. ! Karatasakis A, Tarar MN, Karpalotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Moses JW, Kirtane AJ, Parikh M, Garcia S, Doing A, Pershad A, Shah A, Patel M, Bahadorani J, Shoultz CA Jr, Danek BA, Thompson CA, Banerjee S, Brilakis ES. Guidewire and microcatheter utilization patterns during antegrade wire escalation in chronic total occlusion percutaneous coronary intervention: Insights from a contemporary multicenter registry. *Catheter Cardiovasc Interv.* 2016 May 17. doi: 10.1002/ccd.26568.
157. ! Nguyen-Trong PK, Alaswad K, Karpalotis D, Lombardi W, Grantham JA, Lembo N, Kandzari D, Karatasakis A, Karacsonyi J, Danek BA, Rangan BV, Roesle M, Ayers CR, Thompson CA, Banerjee S, Brilakis ES. Use of Saphenous Vein Bypass Grafts for Retrograde Recanalization of Coronary Chronic Total Occlusions: Insights From a Multicenter Registry. *J Invasive Cardiol.* 2016 Jun;28(6):218-24.
158. ! Karpalotis D, Karatasakis A, Alaswad K, Jaffer FA, Yeh RW, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Doing A, Patel M, Bahadorani JN, Moses JW, Kirtane AJ, Parikh M, Ali ZA, Kalra S, Nguyen-Trong PK, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Thompson CA, Banerjee S, Brilakis ES. Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry. *Circ Cardiovasc Interv.* 2016 Jun;9(6). pii: e003434. doi: 10.1161/CIRCINTERVENTIONS.115.003434.

159. ! Christakopoulos GE, Karpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman RM, Lombardi W, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane A, Parikh M, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Christopoulos G, Karatasakis A, Thompson CA, Banerjee S, Brilakis ES. Contrast Utilization During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. *J Invasive Cardiol*. 2016 Jul;28(7):288-94.
160. ! Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M, Kandzari D, Kario K, Mancina G, Weber M, Böhm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. *Eur Heart J* 2017;38: 93-100.
161. ! Karacsonyi J, Alaswad K, Jaffer FA, Yeh RW, Patel M, Bahadorani J, Karatasakis A, Danek BA, Doing A, Grantham JA, Karpaliotis D, Moses JW, Kirtane A, Parikh M, Ali Z, Lombardi WL, Kandzari DE, Lembo N, Garcia S, Wyman MR, Alame A, Nguyen-Trong PK, Resendes E, Kalsaria P, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. *J Am Heart Assoc*. 2016 Aug 20;5(8). pii: e003890. doi: 10.1161/JAHA.116.003890.
162. ! Finn MT, Green P, Nicholson W, Kalra S, Kandzari DE, Lembo N, Thompson CA, Karpaliotis D. Mother-Daughter-Granddaughter Double GuideLiner Technique for Delivering Stents Past Multiple Extreme Angulations. *Circ Cardiovasc Interv*. 2016 Aug;9(8). pii: e003961. doi: 10.1161/CIRCINTERVENTIONS.116.003961.
163. ! Danek BA, Karatasakis A, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel MP, Bahadorani J, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Ali ZA, Parikh M, Garcia S, Nguyen-Trong PK, Karacsonyi J, Alame AJ, Kalsaria P, Thompson C, Banerjee S, Brilakis ES. Effect of Lesion Age on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary US Multicenter Registry. *Can J Cardiol*. 2016 Apr 22. pii: S0828-282X(16)30031-9. doi: 10.1016/j.cjca.2016.04.007.
164. ! Danek BA, Karatasakis A, Karpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Patel MP, Mahmud E, Lombardi WL, Wyman MR, Grantham JA, Doing A, Kandzari DE, Lembo NJ, Garcia S, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Karacsonyi J, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. Development and Validation of a Scoring System for Predicting Periprocedural Complications During Percutaneous Coronary Interventions of Chronic Total Occlusions: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) Complications Score. *J Am Heart Assoc* 2015;5 pii: e004272.

165. ! Karatasakis A, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Bahadorani JN, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Garcia S, Kalsaria P, Karacsonyi J, Alame AJ, Thompson CA, Banerjee S, Brilakis ES. Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. *Int J Cardiol*. 2016 Dec 1;224:50-56. doi: 10.1016/j.ijcard.2016.08.317.
166. ! Karatasakis A, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel MP, Bahadorani JN, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Moses JW, Kirtane AJ, Garcia S, Parikh MA, Ali ZA, Karacsonyi J, Kalra S, Rangan BV, Kalsaria P, Thompson CA, Banerjee S, Brilakis ES. Impact of Proximal Cap Ambiguity on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter US Registry. *J Invasive Cardiol* 2016;28:391-396.
167. ! Giustino G, Mastoris I, Baber U, Sartori S, Stone GW, Leon MB, Serruys PW, Kastrati A, Windecker S, Valgimigli M, Dangas GD, Von Birgelen C, Smits PC, Kandzari D, Galatius S, Wijns W, Steg PG, Stefanini GG, Aquino M, Morice MC, Camenzind E, Weisz G, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Chieffo A, Mehran R. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JACC Cardiovasc Interv* 2016;9:1890-1901.
168. ! Stone GW, Sabik JF, Serruys PW, Simonton CA, Généreux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Pagé P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. *N Engl J Med* 2016.
169. ! Karatasakis A, Iwnetu R, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Kandzari DE, Lembo NJ, Patel M, Mahmud E, Lombardi WL, Wyman RM, Grantham JA, Doing AH, Toma C, Choi JW, Uretsky BF, Moses JW, Kirtane AJ, Ali ZA, Parikh M, Karacsonyi J, Rangan BV, Thompson CA, Banerjee S, Brilakis ES. The Impact of Age and Sex on In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. *J Invasive Cardiol*. 2017 Jan 15. pii: JIC2017115-1.
170. ! Karatasakis A, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel MP, Bahadorani JN, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Ali Z, Parikh M, Garcia S, Danek BA, Karacsonyi J, Alame A, Kalsaria P, Thompson C, Banerjee S, Brilakis ES. Approaches to percutaneous coronary intervention of right coronary artery

- chronic total occlusions: insights from a multicentre US registry. *EuroIntervention*. 2016;12:e1326-e1335.
171. ! Karatasakis A, Danek BA, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Bahadorani JN, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Garcia S, Kalsaria P, Karacsonyi J, Alame AJ, Thompson CA, Banerjee S, Brilakis ES. Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. *Int J Cardiol*. 2016;224:50-56.
172. ! Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Kandzari D, Ormiston J, for the DESSOLVE I and DESSOLVE II Investigators. Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer: five-year outcomes from the DESSOLVE I and II trials. *Eurointervention* 2017
173. ! Kandzari DE, Carlson H, Gott JP, Kaul P, Brown WM. Balloon 'valvuloplasty' for mechanical valve dysfunction. *JACC Cardiovascular Interventions* 2017;13:e47-e49.
174. ! Karacsonyi J, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Mahmud E, Lombardi W, Wyman MR, Doing A, Moses JW, Kirtane A, Parikh M, Ali Z, Kandzari D, Lembo N, Garcia S, Danek BA, Karatasakis A, Resendes E, Kalsaria P, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. Impact of Calcium on Chronic Total Occlusion Percutaneous Coronary Interventions. *Am J Cardiol*. 2017 Jul 1;120(1):40-46. doi: 10.1016/j.amjcard.2017.03.263.
175. ! Karacsonyi J, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Mahmud E, Doing A, Toma C, Uretsky B, Choi J, Moses JW, Kirtane A, Parikh M, Ali Z, Lombardi WL, Kandzari DE, Lembo N, Garcia S, Wyman MR, Martinez-Parachini JR, Karatasakis A, Danek BA, Alame AJ, Resendes E, Rangan BV, Ungi I, Thompson CA, Banerjee S, Brilakis ES. The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. *J Invasive Cardiol*. 2017 May 15. pii: JIC2017515-1.
176. ! Christakopoulos GE, Christopoulos G, Karpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman MR, Lombardi WL, Tarar MN, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh M, Green P, Finn M, Garcia S, Doing AH, Hatem R, Thompson CA, Banerjee S, Brilakis ES. Predictors of excess patient radiation exposure during chronic total occlusion coronary intervention: insights from a contemporary multicentre registry. *Can J Cardiol* 2017;33:478-484.
177. ! Giustino G, Harari R, Baber U, Sartori S, Stone GW, Leon MB, Windecker S, Serruys PW, Kastrati A, Von Birgelen C, Kimura T, Stefanini GG, Dangas GD, Wijns W, Steg PG, Morice MC, Camenzind E, Weisz G, Smits PC, Sorrentino S, Sharma M, Farhan S, Faggioni M, Kandzari D, Galatius S, Jeger RV, Valgimigli

- M, Itchhaporia D, Mehta L, Kim HS, Chieffo A, Mehran R. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. *JAMA Cardiol* 2017;2:855-862.
178. ! Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized, multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system incorporating historical data and utilizing a Bayesian approach. *Am Heart J* 2017.
179. ! Danek BA, Karatasakis A, Tajti P, Sandoval Y, Karpaliotis D, Alaswad K, Jaffer F, Yeh RW, Kandzari DE, Lembo NJ, Patel MP, Mahmud E, Choi JW, Doing AH, Lombardi WL, Wyman RM, Toma C, Garcia S, Moses JW, Kirtane AJ, Hatem R, Ali ZA, Parikh M, Karacsonyi J, Rangan BV, Khalili H, Burke MN, Banerjee S, Brilakis ES. Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. *Am J Cardiol* 2017 Oct 15;120:1285-1292.
180. ! Kandzari DE, Smits PC, Love MP, Ben-Yehuda O, Banai S, Robinson SD, Jonas M, Kornowski R, Bagur R, Iniguez A, Danenberg H, Feldman R, Jauhar R, Chandna H, Parikh M, Perman GY, Balcells M, Markham P, Ozan MO, Genereux P, Edelman ER, Leon MB, Stone GW. Randomized comparison of ridaforolimus-eluting and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the BIONICS trial. *Circulation* 2017;136:1304-1314.
181. ! Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system utilizing a Bayesian approach. *Am Heart J*, Published online 5 August 2017.
DOI:<http://dx.doi.org/10.1016/j.ahj.2017.08.001>
182. ! Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R, for the BIOFLOW V Investigators. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. *Lancet*, Published online 26 August 2017. DOI: [http://dx.doi.org/10.1016/S0140-6736\(17\)32249-3](http://dx.doi.org/10.1016/S0140-6736(17)32249-3).
183. ! Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M on behalf of the SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive

medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet*. Published online 28 August 2017. DOI: [http://dx.doi.org/10.1016/S0140-6736\(17\)32281-X](http://dx.doi.org/10.1016/S0140-6736(17)32281-X).

184. ! Batchelor W, Kandzari DE, Davis S, Tami L, Wang JC, Othman I, Gigliotti OS, Haghghat A, Singh S, Lopez M, Giugliano G, Horwitz PA, Chandrasekhar J, Underwood P, Thompson CA, Mehran R. Outcomes in women and minorities compared with white men 1 year after everolimus-eluting stent implantation. Insights and results from the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study pooled analysis. *JAMA Cardiol*. Published online October 18, 2017. doi:10.1001/jamacardio.2017.3802.
185. ! Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-Yehuda O, Es GV, Taggart DP, Morice MC, Lembo NJ, Brown WM 3rd, Banning A, Simonton CA, Kappetein AP, Sabik JF, Serruys PW, Stone GW, Cohen DJ; EXCEL Investigators. Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease. *J Am Coll Cardiol*. 2017 Oct 20. pii: S0735-1097(17)41279-4. doi: 10.1016/j.jacc.2017.10.036
186. ! Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Kandzari D, Donohoe D, Ormiston J. Long-term outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials. *Eurointervention* 2017; doi 10.4244/EIJ-D-17-00230
187. ! Chandrasekhar J, Baber U, Sartori S, Stefanini G, Sarin M, Vogel B, Farhan S, Camenzind E, Leon M, Stone G, Serruys P, Wijns W, Steg PG, Weisz G, Chieffo A, Kastrati A, Windecker S, Morice MC, Smits P, von Birgelen C, Mikhail G, Itchhaporia D, Mehta L, Kim HS, Valgimigli M, Jeger R, Kimura T, Galatius S, Kandzari D, Dangas G, Mehran R. Effect of increasing stent length on 3-year clinical outcomes in women undergoing PCI with new generation DES: patient level pooled analysis of randomized trials from the WIN-DES initiative. *JACC Cardiovascular Interventions* 2018;11:53-65.
188. ! Faggioni M, Baber U, Maleki ND, Giustino G, Sartori S, Aquino M, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, Valgimigli M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Dangas GD, Morice MC, Mehran R, et al. Effects of body mass index on clinical outcomes in women undergoing percutaneous coronary intervention with drug-eluting stents: results from a patient-level pooled analysis of randomized controlled trials. *JACC Cardiovascular Interventions* 2018;11:68-76.
189. ! Kosmidou I, Chen S, Kappetein AP, Serruys PW, Gersh BJ, Puskas JD, Kandzari DE, Taggart DP, Morice MC, Buszman PE, Bochenek A, Schampaert E, Pagé P, Sabik JF 3rd, McAndrew T, Redfors B, Ben-Yehuda O, Stone GW. New-onset atrial fibrillation after PCI or CABG for left main disease: the EXCEL trial. *J Am Coll Cardiol* 2018;71:739-748.

190. ! Danek BA, Basir MB, O'Neill WW, Alqarqaz M, Karatasakis A, Karpaliotis D, Jaffer FA, Yeh RW, Wyman M, Lombardi WL, Kandzari D, Lembo N, Doing A, Patel M, Mahmud E, Choi JW, Toma C, Moses JW, Kirtane A, Parikh M, Ali ZA, Garcia S, Karacsonyi J, Rangan BV, Thompson CA, Banerjee S, Brilakis ES, Alaswad K. Mechanical circulatory support in chronic total occlusion percutaneous coronary intervention: insights from a multicenter U.S. registry. *J Invasive Cardiol* 2018;30:81-87.
191. ! Paradies V, Ben-Yehuda O, Jonas M, Banai S, Iñiguez A, Perlman GY, Kandzari DE, Stone GW, Smits PC. A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: six-month angiographic and one-year clinical results of the NIREUS trial. *EuroIntervention* 2018;14:86-93.
192. ! Tajti P, Karpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Holper E, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Rangan BV, Ungi I, Banerjee S, Brilakis ES. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update from the PROGRESS CTO Registry. *JACC Cardiovasc Interv* 2018 Apr 26. doi: 10.1016/j.jcin.2018.02.036.
193. ! Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K; SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *Lancet* 2018 May 22. doi: 10.1016/S0140-6736(18)30951-6

Non-refereed Publications

1. ! Kandzari DE, Behar VS, Sketch MH, Kereiakes DJ, Shimshak T, Broderick T, Young J, Runyon JP, Safian RD, Kern M, Colombo A. Extensive thrombus prior to elective percutaneous coronary intervention. *J Invasive Cardiol* 2001;13:38-52.
2. ! Kandzari, DE, Sketch NH. Saphenous vein graft disease: a left main equivalent. *J Invas Cardiol* 2001;13:665-668.
3. ! Kandzari DE, O'Shea JC, Kay J, Donahue M, Rao S. Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001. *Am Heart J* 2002;143:217-228.
4. ! Kandzari DE, O'Shea JC, Kay J, Donahue M, Rao S. Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001. *MDconsult.com*. February 11, 2002.

5. ! Nguyen CM, Kandzari DE, Peter RH, Harrington RA, Sketch MH. The bent stent. *J Invasive Cardiol* 2002;14:54-56.
6. ! Nguyen CM, Liao L, Trichon B, Saint-Jacques H, Kandzari DE, Donahue M, Nguyen C, Kaul P. Highlights from the American College of Cardiology Annual Scientific Sessions 2002: March 17 to 20. *Am Heart J* 2002;144:549-560.
7. ! Serruys PW, Meier B, Kandzari DE. Clinical decision making: treatment of bifurcation disease. *J Invas Cardiol* 2003.
8. ! Kandzari DE, Muhlestein JB. Clinical decision making: catheter-induced spasm of the left main coronary artery due to anatomic "kinking" in its course (commentary). *J Invas Cardiol* 2005;17:194.

Chapters in Books

1. ! Gips SJ, Kandzari DE, Goldschmidt-Clermont PJ. Growth factor receptors, phospholipases, phospholipid kinases and actin reorganization. *Sem Cell Bio* 1994;5:201-208.
2. ! Kandzari DE, Goldschmidt-Clermont PJ. Regulation of the actin cytoskeleton by inositol phospholipid pathways. *Subcell Biochem* 1996;26:97-114.
3. ! Kandzari DE, Harrington RA. The coagulation system. Acute myocardial ! infarction and other ischemic syndromes, 2nd ed. 2000. !
4. ! Kandzari DE, Jollis JG. Quality of coronary disease report cards. *Acute Coronary Syndromes*, 2nd ed. 2001.
5. ! Kandzari DE, Califf RM. Glycoprotein IIb/IIIa inhibitors in cardiology: the future. In: *GP IIb/IIIa inhibitors in cardiology*, A.M. Lincoff, ed. Humana Press, Inc.: Totowa, NJ. 2003.
6. ! Stone G, Kandzari DE, Grimes C. Integrating Coronary Stents and Glycoprotein IIb/IIIa Inhibitors into a Mechanical Reperfusion Strategy: The CADILLAC and ADMIRAL Trials. In: *Management of Acute Myocardial Infarction*. JE Tchong, ed. 2003.
7. ! Kandzari DE, Harrington RA. The coagulation system. Acute myocardial ! infarction and other ischemic syndromes, 3rd ed. 2003. !
8. ! Patel M, Kandzari, DE, Harrington RA. How to read clinical trials in interventional cardiology.
9. ! Kandzari DE. Antiplatelet therapies in contemporary percutaneous coronary intervention. SB King, ed.
10. Adams G, Kandzari DE, Mark DB. Overview of treatment selection for multivessel disease. DR Holmes, ed.

11. Lavi S, Kandzari DE, Barsness GW. Epidemiology of cardiovascular disease and refractory angina. DR Holmes, Barsness GW, eds.
12. Duggirala HJ, Kandzari, DE, Gross TP. Cardiovascular devices: drug eluting stents. Medical Device Epidemiology and Surveillance. S. Lori Brown, ed. 2007.
13. Barker CM, Kandzari DE. *Chronic Total Coronary Occlusions. Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease*. D. Mukherjee, E.R. Bates, M.Roffi, D.J. Moliterno, ed. 2010.
14. Barsness GW, Kandzari DE. Elective intervention for stable angina or silent ischemia. *Textbook of Interventional Cardiology*. E. Topol, ed. 2011.
15. Kandzari DE. Foreword: Transradial Access: Techniques for Diagnostic Angiography and Percutaneous Intervention. H. Cohen, ed. 2013.
16. Kandzari DE. Treatment of chronic total coronary occlusions with drug-eluting stents: overview of angiographic and clinical outcomes. Waksman R, Saito S, eds. *Chronic Total Occlusions: A Guide to Recanalization*, Wiley-Blackwell, 2013.
17. Barsness GW, Kandzari DE. Elective intervention for stable angina or silent ischemia. *Textbook of Interventional Cardiology*. E. Topol, ed. 2014.
18. Kandzari DE. Chronic total occlusion revascularization. *Cardiovascular Intervention, A Companion to Braunwald's Heart Disease*. D. Bhatt, ed. 2014.
19. Kandzari DE, Yang YJ, Xu B, Gao RL. Transradial percutaneous revascularization for unprotected left main coronary artery disease: an evolution in evidence and technique. O. Bertrand, S.V. Rao, eds. 2015.
20. Patel MR, Kandzari DE, Shah R, Harrington RA. Reading Clinical Trials. Fearon WF Yeung A Samady H, eds. *Interventional Cardiology*, McGraw Hill, 2015.
21. Kar S, Mukherjee D, Kandzari DE. A clinical approach and comprehensive review of percutaneous revascularization of coronary chronic total occlusion. *Cardiovascular Catheterization and Intervention, 2nd Edition*. D. Mukherjee, E. Bates, M. Roffi, R. Lange, D. Moliterno, eds. CRC Press, 2018.
22. Kaira S, Karpaliotis D, Kandzari DE. In: Chronic Total Occlusions. In: Rao S., ed. Cardiac Catheterization and Interventional Cardiology Self-Assessment Program, version 5. American College of Cardiology 2017. Accessible online at <http://www.acc.org/cathsap5>.
23. Kandzari DE. *Stenting of CTO Lesions*. Manual of CTO Interventions, 2nd edition. E. Brilakis, ed. 2017.
24. Patel MR, Kandzari DE, Shah R, Harrington RA. Reading Clinical Trials. Fearon WF Yeung A, Samady H, eds. *Interventional Cardiology 2nd Edition*, Cengage, 2017.

25. Kandzari DE, Karpaliotis D. *Chronic Total Occlusions. 1001 Questions: An Interventional Cardiology Board Review, 2nd Edition*. D. Mukherjee, L. Cho, S. Chatterjee, R. Lange, D. Moliterno, ed. Lippincott, 2017.

Published Scientific Reviews

1. ! Kandzari DE, Tchong JT. Contrast nephropathy. Harrison's online textbook of medicine. harrisonsonline.com. August, 2000.
2. ! Kandzari, DE, editor. American College of Cardiology American Heart Association Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines) Pocket Guidelines. DCRI publications: 2001.
3. ! Goldschmidt-Clermont PJ, Kandzari DE, Khouri S, Ferrari M. Nanotechnology needs for cardiovascular sciences. *Biomedical Microdevices* 2001;3:83-88.
4. ! Kandzari DE, Califf RM. Target versus GUSTO IV: appropriate use of abciximab versus small molecule inhibitors for unstable angina and PCI. *Curr Opin Cardiol* 2002.
5. ! Goldschmidt-Clermont PJ, Kandzari DE, Sketch MH, Phillips HR. Inflammation, platelets, and GP IIb/IIIa inhibitors. *J Invas Cardiol* 2002;14 (Suppl):18-26E.
6. ! Kandzari DE, Mahaffey KW. Clinical experience with glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. *J Intervent Cardiol* 2002;15:121-130.
7. ! Kandzari DE, Tchong JE, Zidar JP. Coronary artery stents: evaluating new designs for contemporary percutaneous intervention. *Cathet Cardiovasc Intervent* 2002;56:562-576.
8. ! Kandzari DE, Zidar JP. Drug-eluting stents: new frontiers for contemporary percutaneous coronary intervention. Harrison's online textbook of medicine. harrisonsonline.com. November, 2002.
9. ! Mayes CE, Kandzari DE, Goldschmidt-Clermont PJ, Phillips HR. Complimentary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. *J Invas Cardiol* 2002;14 (Suppl):36-46E.
10. Kandzari DE, Rebeiz AG, Wang A, Sketch MH, Jr. Contrast nephropathy: an evidence-based approach to prevention. *Am J Therapeutics* 2003;3:395-405.
11. Kandzari, DE. A rationale for chronic total coronary occlusion revascularization: an evidence-based review of clinical trials. *J Invas Cardiol* 2004;16 (Suppl):3-6.
12. Kandzari DE. Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. *Curr Cardiol Rep* 2004;6:279-286.

13. Kandzari DE. The challenges of chronic total coronary occlusions: an old problem in a new perspective. *J Intervent Cardiol* 2004;4:259-257.
14. Kandzari DE. Assessment of coronary stenosis severity and plaque characterization with multi-row detector CT angiography. *Consultations in Computed Tomography*, Vol. 108, August 2005.
15. Kandzari DE, Dery JP, Armstrong PW, Douglas DA, Zettler ME, Hiding KG, Friesen AD, Harrington RA. MC-1 (pyridoxal-5'-phosphate): novel therapeutic applications to reduce ischemic injury. *Expert Opin Investig Drugs* 2005;14:1435-1442.
16. Singh KP, Patel MR, Zidar JP, Kandzari DE. Peripheral arterial disease: an overview of endovascular therapies and contemporary treatment strategies. *Rev Cardiovasc Med* 2006; 7:55-68.
17. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting Endeavor stent. *J Intervent Cardiol* 2006;19:405-413.
18. Tricoci PL, Newby LK, Kandzari DE, Harrington RA. Present and evolving role of eptifibatid in the treatment of acute coronary syndromes. *Expert Rev Cardiovasc Ther.* 2007 May;5(3):401-412.
19. Kandzari DE. Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies. *Rev Cardiovasc Med.* 2006;7 Suppl 3:S43-52.
20. Kandzari DE. Evolving Antithrombotic Treatment Strategies for Acute ST-Elevation Myocardial Infarction. *Rev Cardiovasc Med.* 2006;7 Suppl 4:S29-37.
21. Kandzari DE. Anticoagulation in the cath lab: a contemporary approach. Introduction. *Rev Cardiovasc Med.* 2006;7 Suppl 3:S1-2.
22. Gershlick A, Kandzari DE, Leon MB, Wijnd W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE, for the ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. *Am J Cardiol* 2007;100:45M-55M.
23. Barker CS, Kandzari DE. Sirolimus-eluting Cypher stent: a standard of comparison. *Cardiac Interv Today*, September 2008;1-5.
24. Nayak K, White AA, Cavendish JJ, Barker CM, Kandzari DE. Anaphylactoid reactions to radiocontrast agents: prevention and treatment in the cardiac catheterization laboratory. *J Invas Cardiol* 2009;21:548-551.
25. Kandzari DE. Development and clinical performance of the zotarolimus-eluting Endeavor coronary stent. *Expert Rev Med Devices* 2010;7:449-459.

26. Gunda S, Kandzari DE, Kirtane AJ. The end of ENDEAVOR IV: the stent comparison trial's final follow-up. *Expert Rev Cardiovasc Ther.* 2013;11(8):941-943.
27. Pourafshar N, Karimi A, Alaei-andabili SH, Kandzari DE. Renal denervation: past, present and future. *Cardiovascular Innovations and Applications* 2016;1:253-263.
28. Shlofmitz E, Martinsen BJ, Lee M, Rao SV, Généreux P, Higgins J, Chambers JW, Kirtane AJ, Brilakis ES, Kandzari DE, Sharma SK, Shlofmitz R. Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. *Expert Rev Med Devices.* 2017 Oct 4:1-13. doi: 10.1080/17434440.2017.1384695.

Editorials, Position, and Background Papers

1. ! Kandzari, Goldschmidt-Clermont PJ. Statins and sudden cardiac death. *JAMA* 1999;281:415.
2. ! Kandzari DE, Tcheng JT, Harrington RA, Sketch MH. "Rescue" glycoprotein IIb/IIIa therapy: bailing out of an already sunken ship. *J Invas Cardiol* 2000. !
3. ! Kandzari DE, Jollis JG. Cardiology, for what it's worth. *Am Heart J* 2000;139:392-393.
4. ! Kandzari DE, Goldschmidt PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. *J Am Coll Cardiol* 2001;38:1028-1032.
5. ! Kandzari DE, Goldschmidt PJ. Making positive out of negative trials. *Am Heart J* 2002;143:950-951.
6. ! Rebeiz A, Kandzari DE, Wang A, Sketch MH. Contrast nephropathy—time for affirmative action. *J Invas Cardiol* 2003;15:23-25.
7. ! Kandzari DE, Mark DB. Intracoronary brachytherapy: time to sell short? ! *Circulation* 2003;106:646-648. !
8. ! Kandzari DE, Tcheng JE. Double Negatives. *Am Heart J* 2003;145:9-11.
9. ! Kandzari DE. Carbon-coated stents. Evidence based Cardiovasc Med ! 2004;8:344-345. !
10. Gurbel PA, Kandzari DE. !Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. www.tct.md.com, August 21, 2006.
11. Kandzari DE. Drug-eluting stent thrombosis: it's never too late. *Nat Med* ! 2006;3:638-639. !

12. Gurbel PA, Kandzari DE. Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. *Neth Heart J* 2007;15(4):148-150.
13. Brown R, Teirstein PS, Kandzari DE. Quality of life with PCI versus medical ! therapy in stable coronary disease. *N Engl J Med* 2008;359:2291. !
14. Price MJ, Kandzari DE, Teirstein PS. Change we can believe in: the hyper-evolution of percutaneous coronary intervention for unprotected left main disease with drug-eluting stents. *Circulation Intervent* 2008. *Circulation Intervent* 2008;1:164-166.
15. Kandzari, DE. Import and export of interventional technique: something to declare at the border. *J Am Coll Cardiol Intv* 2009;2:843-845.
16. Kandzari, DE. Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. *Future Medicine* 2012.
17. Kandzari DE, Grantham JA, MD, Lombardi W, Thompson C. Not all subintimal chronic total occlusion revascularization is alike. *J Am Coll Cardiol*. 2013 Mar 28. doi:pii: S0735-1097(13)01238-2. 10.1016/j.jacc.2013.02.055.
18. Kandzari DE, King SB. A passive limitation to equal access in clinical trials: the Medicare review process. *J Am Coll Cardiol Intv* 2013;6:640-641.
19. Kandzari DE, Sobotka PA. Ready for a marathon, not a sprint: renal denervation therapy for treatment-resistant hypertension. *J Am Coll Cardiol* 2013; doi:10.1016/j.jacc.2013.07.047.
20. Kandzari DE. One size does not fit all. *J Am Coll Cardiol* 2015;65:816-819.
21. Kandzari DE. Can't bare it any longer. *J Am Coll Cardiol Intv* 2015.
22. Kandzari DE, Trudel J; SPYRAL HTN Clinical Investigators, and the Medtronic Spyral Core Development Team. Reply to letter to the editor by Kintur Sanghvi, MD; Allen McGrew, DO; and Kiran Hegde, BE, MBA. *Am Heart J* 2016;180:e3-4.
23. Kandzari DE, Moses JW. Left main disease: at the intersection of surgery and stents. *J Am Coll Cardiol Intervent* 2017;10:2411-2413.
24. Kandzari DE. The day after a primary endpoint. *JACC Cardiovasc Interv* 2018;11:470-472. !

Professional Awards and Special Recognitions

2018 Atlanta Magazine, *Atlanta's Top Doctors*

2017 Atlanta Magazine, *Atlanta's Top Doctors*

2016 Montague Boyd Excellence in Publishing Award

2016 Atlanta Magazine, *Atlanta's Top Doctors*
2016 Piedmont Heart Institute Physician of the Year 2015
2015 Atlanta Magazine, *Atlanta's Top Doctors*
2015 Montague Boyd Excellence in Publishing Award
2014 Atlanta Magazine, *Atlanta's Top Doctors*
2013 Atlanta Magazine, *Atlanta's Top Doctors*
2012 U.S. News and World Report, Top 1% of Nation's Cardiologists
2013 Montague Boyd Excellence in Publishing Award
2012 Atlanta Magazine, *Atlanta's Top Doctors*
2011 Atlanta Magazine, *Atlanta's Top Doctors*
2007 Standard of Leadership Award, Johnson & Johnson
2003 TCT2003 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award
2002 Clinical Site Coordinators' Cardiology Research Award, Duke University
2001 Robert "Jess" H. Peter Award in Interventional Cardiology, Duke University
1999 Smith Kline Beecham Preceptorship Award in Cardiology
1995 E.E. Owen Award for Outstanding Clinical Achievement
1994 Duke University Medical Senior Scholarship Award
1993 Stanley J. Sarnoff Fellowship in Cardiovascular Science
1993 Alpha Omega Alpha Medical Honorary
1992 Joseph E. Markee Memorial Award in Anatomy

National Leadership Roles in Clinical Trials

ONYX US DAPT, Co-Principal Investigator
CRYSTAL Trial, International Co-Principal Investigator
SAPPHIRE Trial, Principal Investigator
TARGET BP, Co-Principal Investigator
OPTIMUM, Co-Principal Investigator

SHIELD II, Co-Principal Investigator
SPYRAL Program, Co-Principal Investigator
BIOFLOW V Biotronik Osiro Clinical Trial Program, Principal Investigator
BIONICS BioNir DES Program, International Principal Investigator
ECLIPSE, Steering Committee
SYMPPLICITY HTN 4, Co-Principal Investigator
SYMPPLICITY HTN 3, Steering Committee
Promus ELEMENT US Post Market Registry, Principal Investigator
ILLUMENATE, Data Safety Monitoring Board
EMERGE, Principal Investigator
EXPERT CTO, Principal Investigator
EXCEL, National Leader (PCI)
CYPRESS, Co-Principal Investigator
RES-ELUTION III, Co-Principal Investigator
SEASIDE, Co-Principal Investigator
ENDEAVOR IV, Co-Principal Investigator
ENDEAVOR III, Co-Principal Investigator
ACROSS-Cypher/ Total Occlusion Studies of Coronary Arteries 4, Principal Investigator
GRAVITAS, Chairman, Clinical Events Committee
Nesterone Randomized Trial, Data Safety Monitoring Committee
CROSS Trial, Principal Investigator
Sprinter Legend 1.25 Trial, Principal Investigator
ACROSS Registry, co-Principal Investigator
ANTI-INFLAM, Principal Investigator
Cardiac MRI and Chronic Total Occlusion Study, Principal Investigator
CINEMA, Principal Investigator
COMBAT, co-Principal Investigator
LOWTEMP, co-Principal Investigator
MEND-1, co-Principal Investigator
EVENT Drug Eluting Stent Registry, Steering Committee Member
MEND-CABG, Co- Principal Investigator

National Program Committees/ Professional Society Leadership

ACC2006 Vascular Planning Committee, Co-chairperson
SCAI 2006 Annual Program Co-chairperson
2006 Emerging Techniques in Cardiovascular Imaging: Comparing the Old to the New:
2006 A Cardiologist's Guide to MRI, CTA, and Echo, Course Co-director
TCT2005, TCT2006 Organizational and Planning Committee
2008 Asian Interventional Cardiovascular Therapeutics, International Advisory Board
2008 Samoff Cardiovascular Endowment, Board of Directors
2008 19th Annual Scripps Clinic Coronary Interventions, Course Co-Director
2009 Chronic Total Occlusion Summit, Course Co-Director
2009 International Heart Forum, Transradial Intervention International Course, Course
Co-Director
2009 20th Annual Scripps Clinic Coronary Interventions, Course Co-Director
2010 Chronic Total Occlusion Summit, Course Co-Director
2010 China Interventional Therapeutics, Scientific Committee Member
ACC2010/i2 Summit Program Committee
2010 21th Annual Scripps Clinic Coronary Interventions, Course Co-Director

2010 2nd Transradial Catheterization Therapeutics, China Heart Congress/International Heart Forum 2010, Co-Director
ACC2011/i2 Summit Program Committee
2011 Transcatheter Therapeutics Left Main Summit, Co-Director
2011 Society for Coronary Angiography and Interventions (SCAI) Annual Sessions, Program Committee
2011 Transcatheter Therapeutics (TCT), Scientific Program Organizational Committee
2011 22nd Annual Scripps Clinic Coronary Interventions, Course Co-Director
2011 International Technology Exchange, Sydney, Australia, Co-Director
2012 ACC i2 Summit Abstract Grading Committee, Co-Chair
2012 TCT Complex Coronary Interventions: Left Main and CTO Summit, Co-Director
2013 ACC TCT/i2 Summit Stable Angina Working Group, Chair
Circulatory Devices Panel Voting Member, Edwards Sapien Transcatheter Valve, Gaithersburg, MD, June 13, 2012
23rd Annual Scripps Clinic Coronary Interventions, Course Co-Director
Co-Director, 7th Annual Technology Exchange, Sydney, Australia, November 15-17, 2012
2013 SCAI CTO Regional Training Program, Co-Chair
2013 RADIAL International Academic Board
2013 Cardiovascular Revascularization Therapeutics (CRT2013) Program Committee
2013 Cardiology Napa Valley 2013, Co-Director
2013 SCAI 2013, Program Committee
2014 ACC I2 Summit, Co-Chair
Circulatory Devices Panel Voting Member, BLOCK HF Trial, Gaithersburg, MD, October 11, 2013
Circulatory Devices Panel Voting Member, WATCHMAN Trial, Gaithersburg, MD, December 8, 2013
Circulatory Devices Panel Voting Member, Extracorporeal Membrane Oxygenation, Gaithersburg, MD, June 2014
Circulatory Devices Panel Voting Member, WATCHMAN Trial, Gaithersburg, MD, October 7, 2014
2014 Chronic Total Occlusion and Left Main Summit, Co-Director
2015 American College of Cardiology I2 Summit, Chair
2015 Latin America Technology and Therapy Exchange Program, Co-Chair
2015 TCT 2015 Scientific Committee, member; Associate Director
Circulatory Devices Panel Voting Member, Cangrelor, White Oak, MD, April 15, 2015
2016 American College of Cardiology I2 Summit, Chair
TCT 2016 Associate Director
American College of Cardiology CathPCI Steering Committee, Member, April 4, 2016 (3 yr term)
Circulatory Devices Panel, Leadless Pacemakers, Gaithersburg, MD, February 18, 2016
Circulatory Devices Panel, AMPLATZER Patent Foramen Ovale Closure Device, Gaithersburg, MD, May 24, 2016
ACC/SCAI Interventional Board Review 2016, Faculty Member
TCT 2017 Associate Director
TCT2018 Associate Director
SCAI 2019 Coronary Track Program Director

Editorial/Reviewer Appointments and Responsibilities

ACC CATHSAP 2019, Associate Editor
Circulation: Cardiovascular Interventions, Associate Editor
Eurointervention, International Editorial Board
 ACC CATHSAP, version 5, Associate Editor
 ACC CATHSAP version 4, Associate Editor
Transradialworld.org, Editorial Board
The Journal of Medicine, Editorial Board
Progress in Cardiovascular Diseases, Editorial Board
Global Atrial Fibrillation Stroke Prevention Steering Committee, www.theheart.org
Antiplatelet Therapies Steering Committee, www.theheart.org
American Heart Journal, Guest Editor
American Heart Journal, Editorial Board and Associate Editor (2005-2006)
Reviews in Cardiovascular Medicine, Editorial Board
Eurointervention, Guest Editor
Future Cardiology, Editorial Advisory Board
Journal of the American College of Cardiology, Guest Editor
JACC Interventions, Guest Editor
Clinical Research in Cardiology, Editorial Board
 Reviewer: *American Heart Journal*, *American Journal of Cardiology*, *Circulation*,
Catheterization and Cardiovascular Interventions, *Journal of the American College of*
Cardiology, *JACC Interventions*, *Journal of the American Medical Association*,
Circulation Cardiovascular Interventions, *Journal of Sexual Medicine*, *Lancet*
 Reviewer, American Heart Association Scientific Statement, *Contemporary Management*
of Cardiogenic Shock

Organizations and Participation

Alpha Omega Alpha, member
 American College of Cardiology, Fellow
 American College of Physicians, Fellow
 American Heart Association, early career member
 Andreas Gruentzig Society, member
 Sarnoff Cardiovascular Endowment, Board of Directors member
 Society of Coronary Angiography and Interventions, Fellow
 Society of Coronary Angiography and Interventions, Development Committee Co-Chair

Selected Invited Lectures/CME Events

1. ! Duke Cardiology Grand Rounds, May 2000. *Mechanical Circulatory Support*
2. ! Medicine Grand Rounds, Rex Hospital, Raleigh, NC, 2000. *Cardiovascular Disease in Women*
3. ! Duke Clinical Research Conference, October 2001. *Megatrial in Aspirin Dosing*
4. ! Duke Clinical Research Conference, October 2002. *Lowering Adverse Outcomes with Temperature Regulation (LOWTEMP)*
5. ! Transcatheter Therapeutics (TCT) 2002, Washington, DC, September 2002. *Chronic Total Occlusions in Peripheral Arterial Disease*

6. ! Transcatheter Therapeutics 2002, September 2002. *Therapeutic Hypothermia as Adjunctive Therapy in Primary PCI*
7. ! Cardiovascular Associates 21st Annual Symposium on Cardiovascular Disease, Louisville KY, October 2002. *Contemporary Management of Acute Coronary Syndromes*
8. ! 13th Annual William Beaumont/Duke University Cardiovascular Conference, Beaver Creek, CO, Faculty, February, 2003. *Update on Chronic Total Occlusions*
9. ! Medicine Grand Rounds, Ochsner Institute, New Orleans, LA, May 2003. *Contemporary Management of Acute Myocardial Infarction*
10. Vascular Strategies Summit, Chicago, IL, May 2003. *Update in ST-Elevation Myocardial Infarction*
11. Duke Stent Symposium, Faculty, Pinehurst, NC, May 2003. *Novel Catheters for Percutaneous Coronary Intervention*
12. Paris Revascularization Course, Paris, France, May 2003. *Endovascular Cooling as Adjunctive Therapy in AMI*
13. ESPRIT investigator's close-out meeting, Miami, FL, May 2003. *Inflammation and ACS*
14. American College of Cardiology, Colorado Chapter, Denver, CO, July 2003. *Antithrombotic Therapies in ACS and Contemporary PCI*
15. Medtronic Scientific Advisory Board, Minneapolis, MN, June 2003. *Angiogenesis for Peripheral Arterial Disease*
16. TCT2003 Faculty, Plenary Session, Washington, DC, September 2003. *Unconquered Frontiers: Chronic Total Coronary Occlusions*
17. TCT2003 Faculty, Washington, DC, September 2003. *Plenary Session: New Solutions for Old Problems: Chronic Total Occlusions*
18. TCT2003 Faculty, Washington, DC, September 2003. *ACROSS: Approaches to Chronic Occlusions Registry*
19. Cardiology Grand Rounds, Allegheny General Hospital, Pittsburgh, PA, October 2003. *Antithrombotic Therapies in the Management of ACS and in Contemporary PCI*
20. North American CTO Club Meeting Faculty, Lenox Hill Hospital, New York, December 2003. *A Rationale for Chronic Total Occlusion Revascularization: An Evidence-based Review of Clinical Trials*
21. National Teleconference Series, January 2004. *New Considerations on the Treatment of Patients with NSTEMI ACS*
22. Duke Heart Center, Regional Symposium, January 2004. *Update in Peripheral Arterial Disease*
23. Vail Stent Symposium Faculty, Vail, CO, January 2004. *Evolving Beyond Platelet Inhibition: New Concepts for Antithrombotic Therapies in ACS and Contemporary PCI*
24. Vail Stent Symposium Faculty, Vail, CO, January 2004. *Novel Catheter-based Technologies in Percutaneous Coronary Revascularization*
25. 14th Annual William Beaumont/Duke University Cardiovascular Conference, Beaver Creek, CO, Faculty, February, 2004. *A Rationale for Chronic Total Occlusion Revascularization: An Evidence-based Review of Clinical Trials*
26. 14th Annual William Beaumont/Duke University Cardiovascular Conference, Beaver Creek, CO, Faculty, February, 2004. *Unstable Blood: Inflammation in Cardiovascular Disease*
27. Duke Clinical Research/ US FDA symposium on approval of new technologies in coronary revascularization, ACC Heart House, February 2004. *Participant*

28. Texas Heart Institute, Cardiology Grand Rounds, February 2004. *Evolving Beyond Platelet Inhibition: New Concepts for Antithrombotic Therapies in ACS and Contemporary PCI*
29. Interventions 2004 Faculty, Atlanta, GA, April 2004. *Update in Chronic Total Occlusion Revascularization: New Solutions for Old Problems*
30. 2004 American College of Cardiology Scientific Sessions, New Orleans, LA, 2004. *Complications in PCI: Chronic Total Occlusions*
31. 2004 European Society of Cardiology Scientific Sessions, Munich, Germany, August 2004. *ENDEAVOR 4: Randomized trial of the ABT-578 drug-eluting Endeavor stent with the TAXUS stent*
32. TCT2004 Faculty, Washington, DC, September 2004. *Plenary Session: A Rationale for Chronic Total Coronary Occlusion Revascularization: An Evidence-based Review of Clinical Trials and Technology*
33. New Cardiovascular Horizons, New Orleans, LA, October 2004. *New Perspectives on Antithrombotic Therapy and Drug-Eluting Stents in Contemporary Percutaneous Coronary Intervention*
34. Cardiology Grand Rounds, Rush University, Chicago, IL, November, 2004. *An Evolution of Antithrombotic Therapies in ACS and Contemporary PCI*
35. International Symposium of Cardiology: Procordis 40th Anniversary, Niteroi Hospital, Niteroi, Brasil, December 3, 2004. *Unstable Blood: Inflammation, Vulnerable Plaque, and Cardiovascular Disease. Identification, Implications, and Treatment of Unstable Coronary Lesions.*
36. International Symposium of Cardiology: Procordis 40th Anniversary, Niteroi Hospital, Niteroi, Brasil, December 4, 2004. *Unconquered Frontiers in Contemporary PCI: An Evidence-based Rationale for PCI in a DES Era.*
37. International Symposium of Cardiology: Procordis 40th Anniversary, Niteroi Hospital, Niteroi, Brasil, December 4, 2004. *Diagnostic and Therapeutic Potential of Stem Cells in Cardiovascular Disease: Steps Closer to Finding the Fountain of Youth*
38. 18th Annual Meeting of the Japanese Coronary Association, December 10, 2004, Kumamoto, Japan. *Evolving Understanding of Antithrombotic Therapies in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention.*
39. 18th Annual Meeting of the Japanese Coronary Association, December 10, 2004, Kumamoto, Japan. *Unconquered Frontiers—The Challenge of Complex Coronary Intervention.*
40. Whistler Course, January 29, 2005, Whistler, Canada. *An Evidence-based Rationale for CTO Revascularization.*
41. Cardiology Grand Rounds, February 2, 2005, Shands Hospital, Jacksonville, FL. *Complex Lesion Treatment with DES in Contemporary PCI.*
42. Chronic Total Occlusion Summit, Cardiovascular Research Foundation, February 4, 2005, New York, New York. *An Evidence-based Rationale for CTO Revascularization: Review of Evidence and Appraisal of New Technologies.*
43. Chronic Total Occlusions, Meet the Experts, March 7, 2005, Orlando, FL. American College of Cardiology 2005 Scientific Sessions.
44. ENDEAVOR Clinical Trials Program, March 5, 2005, Orlando Florida, Cardiovascular Research Foundation Drug Eluting Stent Revolution IV: A Critical Appraisal.
45. San Antonio Cardiovascular Society, April 21, 2005. *An Evidence-based Rationale for CTO Revascularization: Review of Evidence and Appraisal of New Technologies.*

46. 9th Annual Duke Spring Cardiovascular Symposium, April 23, 2005, Pinehurst, NC. *Multi-row detector CT Angiography: New Perspectives on Noninvasive Coronary and Vascular Imaging.*
47. 14th Annual Scientific Sessions, Brazilian Society of Cardiology, April 27, 2005, Rio de Janeiro, Brasil. *The Vulnerable Atherosclerotic Plaque: Definition, Identification and Implications of Unstable Coronary Atherosclerotic Lesions.*
48. American College of Cardiology CT Coronary Angiography Review Course, April 30, 2005, Milwaukee, WI. *Indications, Guidelines and Appropriateness Criteria for CTA – Where We Are and Where We Need To Go*
49. Providence Heart and Vascular Institute Research Symposium, May 9, 2005, Portland, Oregon. *New Insights in Pharmacotherapy for the Interventional Cardiologist.*
50. Abbott Vascular Webcast, The Challenges of Chronic Total Occlusions: Overview of Rationale, Technique and Technology (CME event), June 1, 2005. *Novel Techniques and Technologies for CTO Revascularization.*
51. Intervention2005, Las Vegas, NV, June 3, 2005. *Treatment Strategies for Non-ST-Elevation Acute Coronary Syndromes.*
52. 14th Interventional Cardiology Symposium, Montreal Heart Institute, June 16-17, 2005, Montreal, Canada. *Chronic Total Occlusion Revascularization: New Perspectives on an Old Problem.*
53. Hong Kong Sanatorium and Hospital Annual Scientific Meeting, June 27, 2005, Hong Kong. *Endeavor Clinical Trials Program and Endeavor II Trial Results.*
54. MedReviews in Cardiovascular Medicine, July 15, 2005 (Co-chairperson). *Novel Antiplatelet and Antithrombin Therapies.*
55. Summer in Seattle SIS 2005 Interventional Program, July 20, 2005, Seattle, WA. *Update on Rationale and Technologies for CTO Revascularization.*
56. Malaysian Cardiovascular Interventional Symposium 2005, July 27-30, 2005, Kuala Lumpur, Malaysia. *Bare Metal Stents versus Drug-eluting Stents: Their Role in PCI Today.*
57. New Cardiovascular Horizons Meeting, October 26, 2005, Miami, FL. *Atherosclerosis, Plaque Biology and Genomics: Potential for Disease Management and Diagnosis Through Gene Expression Profiling.*
58. 1st Annual Scientific Meeting of the Coronary Interventional Club of Thailand, November 25, 2005, Bangkok, Thailand. *Clinical Relevance and Rationale for CTO Revascularization.*
59. 1st Annual Scientific Meeting of the Coronary Interventional Club of Thailand, November 25, 2005, Bangkok, Thailand. *Evidence-based Perspectives on Drug-Eluting Stents.*
60. 2nd International Cardiovascular Symposium, December 2, 2005, Niteroi, Brazil. *Clinical Approach to the Identification and Treatment of Renal Artery Stenosis.*
61. Columbia University Medical Center, Cardiac Catheterization Laboratory Grand Rounds, December 6, 2005, New York, New York. *Noninvasive Imaging for Interventionalists: Role of Noninvasive Imaging for Clinical Decision- Making in the Catheterization Laboratory.*
62. STRIVE Program: Strategies and Therapies for Reducing Ischemic and Vascular Events, December 15, 2005, Boston, MA. *Frequency and Implications of Stent Thrombosis Following DES Use in Contemporary Clinical Practice: Overview of the Incidence, Predictors and Implications of Drug-Eluting Stent Thrombosis.*
63. PCI Summit 2006, January 11, 2006, Park City, Utah. *Latest Advances in Atherectomy and Debulking Techniques.*

64. PCI Summit 2006, January 14, 2006, Park City, Utah. *!Role of Noninvasive Imaging with CT Angiography for Cath Lab Decision Making.*
65. PCI Summit 2006, January 14, 2006, Park City, Utah. *!The Paclitaxel -Eluting Stent: From Taxus to Liberte and into the Future: The Boston Scientific DES Program.*
66. 15th Annual Whistler Interventional Cardiology Meeting, January 24, 2006, Whistler, BC, Canada. *An Evidence-based Rationale for Successful CTO Revascularization.*
67. American Society of Echocardiography, February 2, 2006, Marco Island, Florida. *ABC's of Coronary CTA: Getting Started with Coronary CT Angiography.*
68. American Society of Echocardiography, February 3, 2006, Marco Island, Florida. *Noninvasive Imaging for Peripheral Arterial Disease: Perspectives on CT and MR for Assessment of Atherosclerotic Peripheral Arterial Disease.*
69. 15th Annual Cardiovascular Conference at Beaver Creek, February 15, 2006, Avon, Colorado. *Myocardial Perfusion in Acute MI.*
70. Morgan Stanley 9th Annual Interventional Cardiology Conference, February 22, 2006, New York, NY. *State of the Art for Coronary Stents: Balancing Safety and Efficacy.*
71. 3rd International Chronic Total Occlusion Summit, February 23, 2006, New York, NY. *The Latest Evidence Based Medicine in CTO Therapy: Emphasis on Drug-Eluting Stents.*
72. Singapore Live 2006, February 28, 2006, Singapore. *Late Loss and its Relationship to events after DES Stenting.*
73. Singapore Live 2006, February 28, 2006, Singapore. *!US Techniques/Approaches to CTO.*
74. ACC 2006, March 11, 2006, Atlanta Georgia. *!Enter the Drug-Eluting Stent Revolution V: A Critical Appraisal of DES, Safety, and Efficacy.*
75. ACC 2006, March 13, 2006, Atlanta Georgia. *!Endeavor Trials - Drug-Eluting Stents: Results from Clinical Trials.*
76. ACC 2006, March 14, 2006, Atlanta, Georgia. *!ACCEL Interview – ENDEAVOR Trials.*
77. ACC 2006, March 14, 2006, Atlanta, Georgia. *!Chronic Total Occlusions: Percutaneous Coronary Intervention.*
78. Med Reviews CME Event, March 18, 2006, New York, NY. *!Anticoagulation in the Cath Lab: A Contemporary Approach. New Developments in Antiplatelet and Anticoagulant Therapy.*
79. Atlanta Cardiology Catheterization Lab Approaches for Success VII, March 22, 2006, Atlanta, GA. *Chronic Total Occlusions: Other Complex / Challenging Cases.*
80. 12th Annual Interventional Cardiology Fellows Course, March 29, 2006, San Jose, CA. *CTO Angioplasty I: Pathology, Rationale and Predictors of Success.*
81. Angioplasty Summit 2006 TCT Asia Pacific, April 26, 2006, Seoul, Korea. *!Drug Eluting Stent Summit I. Overview of Endeavor Clinical Trials Program.*
82. Angioplasty Summit 2006 TCT Asia Pacific, April 26, 2006, Seoul, Korea. *!Drug Eluting Stent Thrombosis: Balancing Efficacy with Safety.*
83. Angioplasty Summit 2006 TCT Asia Pacific, April 27, 2006, Seoul Korea. *Chronic Total Occlusions: Evidence Based Rationale for Recanalization and DES.*
84. SCAI 29th Annual Scientific Sessions, May 10, 2006, Chicago, IL. *Drug Eluting Stents: Complex Lesions, The Latest Data.*

85. SCAI 29th Annual Scientific Sessions, May 12, 2006, Chicago, IL. *Chronic Total Occlusions: Why Open CTO's; Whom Do We Treat?*
86. Euro PCR 2006, May 18, 2006, Paris, France. *Chronic Total Occlusions: Advanced Strategies 2006 from Japan.*
87. 8th Annual International Symposium on MDCT, June 17, 2006, San Francisco, CA. *Evidence- Based Rationale for Coronary CT Angiography.*
88. 8th Annual International Symposium on MDCT, June 17, 2006, San Francisco, CA. *Non Invasive Imaging with CT Angiography for Interventional Cardiology Applications.*
89. 15th Annual Japanese Society of Interventional Cardiology, June 23, 2006, Fukuoka, Japan. *Stent Migration or Fracture? Clinical Implications of Stent Fracture Following Total Occlusion revascularization.*
90. 3rd Malaysian Cardiovascular Interventional Symposium with Live Transmission, July 12, 2006, Kuala Lumpur, Malaysia. *Stent Malapposition: Is it Clinically Relevant?*
91. 3rd Malaysian Cardiovascular Interventional Symposium with Live Transmission, July 13, 2006, Kuala Lumpur, Malaysia. *ENDEAVOR Trials/ Registry.*
92. 3rd Malaysian Cardiovascular Interventional Symposium with Live Transmission, July 14, 2006, Kuala Lumpur, Malaysia. *CTO: The Last Frontier?*
93. Summer in Seattle SIS 2006, July 21, 2006, Bellevue, Washington. *CTO Traditional and Novel Approaches.*
94. Summer in Seattle SIS 2006, July 22, 2006, Bellevue, Washington. *Chronic Total Occlusions: Techniques and Approaches.*
95. PCI Summit Meeting, January 2007, Salt lake City, Utah. *Contemporary PCI with the Cypher Stent: Standard of Compare and Standard of Comparison.*
96. British Cardiac Interventional Society Meeting, January 2007, London, England. *Contemporary PCI with the Cypher Stent: Standard of Compare and Standard of Comparison.*
97. Catheter Revascularization Therapies Conference, FDA Town Hall Meeting, February 2007, Washington, DC. *Cordis Corporation Perspective on FDA Guidance for Drug-Eluting Stents.*
98. American College of Cardiology Scientific Sessions, March 2007, New Orleans, LA. *Debate: Endovascular Therapy is Treatment of Choice for Treatment of Intermittent Claudication.*
99. Angioplasty Summit Cardiovascular Conference, April 2007, Seoul, Korea. *Clinical Considerations for Patient Selection in CTO Revascularization.*
100. ! Stanford Center for Cardiovascular Technology Symposium, May 30, 2007, Palo Alto, CA. *Future Technologies from the Cordis Corporation.*
101. ! Japanese Society of Interventional Cardiology, June 2007, Fukuoka, Japan. *Understanding and Applying the Evidence from Randomized Clinical Trials, Registries and Meta-analyses: Is There a Common Theme?*
102. ! Malaysia Live Cardiovascular Conference, July 2007, Kuala Lumpur, Malaysia. *Clinical Considerations for Patient Selection in CTO Revascularization.*
103. ! Malaysia Live Cardiovascular Conference, July 2007, Kuala Lumpur, Malaysia. *Exploring New Frontiers in PCI: CTO Revascularization in 2007.*
104. ! Malaysia Live Cardiovascular Conference, July 2007, Kuala Lumpur, Malaysia. *Noninvasive Imaging for Interventional Cardiologists: Perspectives on Non-invasive Coronary and Peripheral Arterial Imaging for Cath Lab Decision Making.*
105. ! TOPIC Meeting, July 21, 2007, Tokyo, Japan. *Drug-Eluting Stent Landscape and the Cordis Clinical Trials Program.*

106. Transcatheter Therapeutics 2007, October 2007, Washington, D.C. *Approaches to Chronic Occlusions with Sirolimus Stents: the ACROSS-Cypher/Total Occlusion Study of Coronary Arteries-4 Trial.*
107. Great Wall Cardiovascular Society, October 2007, Beijing, China. *Antiplatelet Therapy and Drug-Eluting Safety: Risks and Benefits of Antiplatelet Therapy in an Era of Drug-Eluting Stents.*
108. Great Wall Cardiovascular Society, October 2007, Beijing, China. *Late Drug-Eluting Stent Thrombosis: Incidence, Predictors and Clinical Implications of Stent Thrombosis.*
109. Medicine Grand Rounds, Loyola University, October 2007, Chicago, IL. *Drug-Eluting Coronary Stent Safety in 2007: Overview of the Incidence, Predictors and Clinical Implications of Drug-Eluting Stent-related Adverse Events.*
110. ! Cardiology Grand Rounds, Scripps Green Hospital, October 2007, La Jolla, CA. *Predicting Late Drug-Eluting Coronary Stent Thrombosis.*
111. ! Australia-New Zealand Cardiovascular Society Conference (ANZET), November 2007, Christ Church, NZ. *Overview of Cordis Clinical Trials Program.*
112. ! 3rd Annual Coronary Interventional Society of Thailand Cardiovascular Conference, November 2007, Bangkok, Thailand. *Drug-Eluting Coronary Stent Safety and Efficacy in 'Real World' Practice.*
113. ! 3rd Annual Coronary Interventional Society of Thailand Cardiovascular Conference, November 2007, Bangkok, Thailand. *Endovascular Treatment for Peripheral Arterial Chronic Total Occlusions: Clinical Outcomes, Challenges and Potential for Disease Management.*
114. ! 16th Annual Beaver Creek Cardiovascular Conference, February 2007, Beaver Creek, CO. *PCI in Perspective: Do Clinical Trials Influence Clinical Decision Making in Percutaneous Coronary Intervention?*
115. ! 3-C Conference on Advances in Cardiovascular Medicine, January 2008, Ahmedabad, India. *Drug Eluting Stents are the Treatment of Choice in Eligible Patients with Coronary Disease: The Evolving Efficacy and Safety of Drug-Eluting Stents.*
116. 3-C Conference on Advances in Cardiovascular Medicine, January 2008, Ahmedabad, India. *Perioperative Management of Patients with Coronary Stents. Overview of Preoperative Assessment and Perioperative Management of Stent Patients Undergoing Non-cardiac Surgery.*
117. 3-C Conference on Advances in Cardiovascular Medicine, January 2008, Ahmedabad, India. *Perioperative Management of Patients with Coronary Stents. Overview of Preoperative Assessment and Perioperative Management of Stent Patients Undergoing Non-cardiac Surgery.*
118. ! SingLive 2008, March 2008, Singapore. *Evidence-based Overview of Drug Eluting Stent Use in Chronic Total Occlusions: Results from the ACROSS/TOSCA-4 Trial.*
119. ! SingLive 2008, March 2008, Singapore. *Clinical Considerations for Patient Selection in Chronic Total Occlusion Revascularization: Whom to Treat, Who Derives Benefit and What Can We Achieve?*
120. ! SingLive 2008, March 2008, Singapore. *Drug Eluting Stent Outcomes in Real World Practice: Spectrum of Efficacy and Safety Among Differing Drug Eluting Stents.*
121. ! SingLive 2008, March 2008, Singapore. *Drug Eluting Stent Outcomes in Real World Practice: Spectrum of Efficacy and Safety Among Differing Drug Eluting Stents.*

122. ! Alliance of Cardiovascular Professionals 2008 Leadership Conference, March 27, 2008, Chicago, IL. *New Developments and Future Technologies in Cardiovascular Disease.*
123. ! American College of Cardiovascular Administrators 19th Annual Leadership Conference, March 27, 2008, Chicago, IL. *Interventional Cardiology in Perspective: An Interplay of Clinical Trials, Public Opinion and Physician Perceptions.*
124. ! 13th Angioplasty Summit- TCT Asia Pacific 2008, April 23, 2008, Seoul, Korea. *Comparative Trials of DES Safety and Efficacy Role of DES in Chronic Total Occlusions: Results of The ACROSS Trial Evaluating SES in Chronic Total Occlusions.*
125. ! 13th Angioplasty Summit- TCT Asia Pacific 2008, April 24, 2008, Seoul, Korea. *Safety of Drug Eluting Stents in Diabetes.*
126. ! Brazilian Society of Interventional Cardiology 2008, June 17, 2008, Recife, Brasil. *Current Perspectives on DES in Contemporary PCI: A Standard of Comparison, A Standard of Care.*
127. ! 2008 Malaysian Live Cardiovascular Conference, July 9, 2008, Kuala Lumpur, Malaysia. *Diabetes in PCI: Therapeutic Challenge for a Global Epidemic.*
128. ! 2008 Malaysian Live Cardiovascular Conference, July 9, 2008, Kuala Lumpur, Malaysia. *Diabetes in PCI: Therapeutic Challenge for a Global Epidemic. Endovascular Therapies for Lower Extremity Peripheral Arterial Disease: Clinical Outcomes, Challenges and Potential for Disease Management.*
129. ! Cardiac and Peripheral Vascular CT 2008: What You Need to Know, September 4, 2008, Las Vegas, Nevada. *Who Should(n't) Have a Coronary CTA Exam?*
130. ! Cardiac and Peripheral Vascular CT 2008: What You Need to Know, September 4, 2008, Las Vegas, Nevada. *Comparative Trials of Coronary CT Angiography and Cardiac Catheterization.*
131. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *Improvement in Left Ventricular Function After Successful CTO Recanalization: Frequency, Correlates and Clinical Implications.*
132. ! Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *New Bioabsorbable Polymer Drug Carrier Systems. The MICELL Rapid Absorption Polymer DES System: Design Concepts and Experimental Studies.*
133. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *Plenary Lecture: Clinical Considerations for CTO Revascularization: Whom to Treat, Who Derives Benefit, and What Can We Achieve?*
134. ! Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *CTO Revascularization Revisited: Rationale, Patient Selection and Evolutionary Approach.*
135. ! Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *The Great Debate. Adjunct Pharmacotherapy for Primary PCI: Heparin plus GP IIb/IIIa Inhibitors Must Still be Considered Standard of Care.*
136. ! American Heart Association Scientific Sessions, November 2008, New Orleans, LA. *Chronic Coronary Total Occlusions, State of the Art: Rationale for Chronic Total Occlusion Percutaneous Revascularization.*
137. ! Taiwan Transcatheter Therapeutics, January 2009, Taipei, Taiwan. *PCI in Perspective: Key Clinical Trials in Interventional Cardiology for 2009.*
138. ! Taiwan Transcatheter Therapeutics, January 2009, Taipei, Taiwan. *The Endeavor Resolute Clinical Trials Program.*

139. Taiwan Transcatheter Therapeutics, January 2009, Taipei, Taiwan. *Overview of the Long-Term Safety and Efficacy of the Endeavor Clinical Trial Program.*
140. ! Courage Quality of Life: How to Manage Patients with Unstable Angina. August 29, 2008, www.theheart.org.
141. ! DES in Complex Patients: A Case-based Discussion. October 28, 2008, www.theheart.org.
142. ! Drug-eluting Stents and Noncardiac Surgery. November 24, 2008, www.theheart.org.
143. ! Why Warfarin Has Been the Mainstay of Anticoagulation and Antithrombin Therapy for Half a Century: Benefits and Limitations. November 28, 2008, www.theheart.org.
144. ! Antiplatelet Options for ACS: the Changing Landscape. February 12, 2009, www.theheart.org.
145. ! Emory Regional Cardiac Catheterization Conference, January 14, 2009, Atlanta, GA. *PCI in Perspective: Lessons Learned in Interventional Cardiology.*
146. ! Chronic Total Occlusion Summit, February 5, 2009, New York, NY and La Jolla, CA. *DES in CTO Revascularization: One Step Forward, Two Steps Back?*
147. Panvascular Summit, February 26, 2009, Park City, Utah. *Left Main Percutaneous Coronary Revascularization: Time for Changing the Standard of Care.*
148. ! CRT 2009, March 5, 2009, Washington, DC. *Impact of CTO Revascularization on Left Ventricular Function.*
149. ! CRT 2009, March 5, 2009, Washington, DC. *DES in Acute Myocardial Infarction: More Trials, But Still at Equipose.*
150. ! CRT 2009, March 6, 2009, Washington, DC. *The Micell Rapid Absorption Polymer DES System.*
151. ! China Interventional Therapeutics, March 19, 2009, Beijing, China. *Key Clinical Trials in Interventional Cardiology for 2009.*
152. ! China Interventional Therapeutics, March 19, 2009, Beijing, China. *DES in Acute Myocardial Infarction: More Trials, But Still at Equipose.*
153. ! China Interventional Therapeutics, March 19, 2009, Beijing, China. *Novel Endovascular Therapies for Lower Extremity Revascularization.*
154. ! American College of Cardiology Scientific Sessions, March 29, 2009, Orlando, FL. *The 'Optimal' Duration of Antiplatelet Therapy: Less is More, More or Less.*
155. ! American College of Cardiology Scientific Sessions, March 31, 2009, Orlando, FL. *Rationale for CTO Revascularization, ACC Fellows' Course.*
156. ! Assessing Long-term Risks and Benefits of Drug-eluting and Bare Metal Stents. March 29, 2009, www.theheart.org.
157. ! What Happened at ACC 2009?: A Scripps Perspective. March 29, 2009, www.theheart.org.
158. ! Cardiac Catheterization Access Sites: An International Perspective and Emphasis on Transradial Intervention. March 30, 2009, www.theheart.org.
159. ! Fifth Annual Cardiology Symposium, Mother Frances Hospital, April 14, 2009, Tyler, TX. *Key Cardiovascular Clinical Trials for 2009.*
160. ! 14th Angioplasty Summit-TCT Asia Pacific 2009, April 22, 2009, Seoul, Korea. *Critical Review of Interventional Options for the SFA: Current Devices and Future Directions.*

161. ! 14th Angioplasty Summit-TCT Asia Pacific 2009, April 23, 2009, Seoul, Korea. *What is the Optimal Duration of Dual Antiplatelet Therapy Following DES Revascularization?*
162. ! 14th Angioplasty Summit-TCT Asia Pacific 2009, April 23, 2009, Seoul, Korea. *Outcomes of Zotarolimus Eluting Stents in Diabetes: Results from the Endeavor IV and E-Five Clinical Trials.*
163. ! 14th Angioplasty Summit-TCT Asia Pacific 2009, April 24, 2009, Seoul, Korea. *Rationale for Chronic Total Occlusion Revascularization.*
164. ! Innovations 2009, April 30, 2009, Washington, DC. *From Clinical Trials to Clinical Practice. When Should DES Be Used?*
165. ! SCAI 2009 Scientific Sessions, May 8, 2009, Las Vegas, NV. *Seeing is Believing: Use of Intravascular Ultrasound in Chronic Total Revascularization.*
166. SCAI 2009 Scientific Sessions, May 8, 2009, Las Vegas, NV. *Uncrossably Crossed Chronic Total Occlusions.*
167. ! Cardiology Grand Rounds, Sharp Memorial Hospital, May 22, 2009, San Diego, CA. *A Clinical Rationale for CTO Revascularization.*
168. ! Cardiology Grand Rounds, University of San Francisco, California, June 3, 2009, San Francisco, CA. *Unprotected Left Main Percutaneous Revascularization: Are We Ready to Change the Guidelines?*
169. Transradial Access for PCI. June 26, 2009, www.theheart.org.
170. ! Hong Kong College of Cardiology, 17th Annual Scientific Congress, June 27, 2009, Hong Kong. *Drug-Eluting Stents in Acute Coronary Syndromes.*
171. ! Hong Kong College of Cardiology, 17th Annual Scientific Congress, June 27, 2009, Hong Kong. *New Drug-Eluting Stent Solutions for Complex Coronary Artery Disease.*
172. ! TOPIC 2009, July 16, 2009, Tokyo, Japan. *Left Main Percutaneous Revascularization: Influence of Stent Technique.*
173. ! TOPIC 2009, July 16, 2009, Tokyo, Japan. *SYNTAX in Clinical Practice: A Practical Approach to How the SYNTAX Trial Influences Clinical Decision Making.*
174. ! TOPIC 2009, July 16, 2009, Tokyo, Japan. *DAPT After DES Revascularization: Risk, Benefit and Still Much to Learn.*
175. ! Emerging Countries Interventional Symposium, August 13, 2009, Vienna, Austria. *Interventional Cardiology in Perspective: Past, Present and Future.*
176. ! PCI for Unprotected Left Main Disease: Are We There Yet? September 22, 2009, www.theheart.org.
177. ! TCT 2009, September 21, 2009, San Francisco, CA. *The Resistant CTO: When a Lesion Won't Dilate.*
178. ! TCT 2009, September 21, 2009, San Francisco, CA. *Clinical Dilemmas for Multivessel Coronary Disease in 2009: Considerations for Revascularization Strategy, Relative Risk and Benefit*
179. 9th Annual Cardiovascular Symposium, October 9, 2009, Wailea, Maui. *PCI for Unprotected Left Main Disease: Are We Ready to Change Practice Guidelines?*
180. ! Cardiology Grand Rounds, Scripps Mercy Hospital, October 1, 2009, San Diego, CA. *TCT2009: Review of High Impact Clinical Trials.*
181. ! Cardiology Grand Rounds, Grossmont Hospital, October 21, 2009, San Diego, CA. *PCI in Perspective: Past, Present and Beyond. Lessons Learned in Interventional Cardiology and Future Directions.*
182. ! University of Texas-Southwestern 9th Annual Cardiovascular Symposium: Frontiers in Interventional Cardiology, October 26, Dallas, TX. *Clinical*

- Considerations for Chronic Total Occlusion Revascularization. Whom to Treat, Who Derives Benefit, What Can We Achieve?*
183. ! 20th Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Technical Considerations for Chronic Total Occlusion Revascularization: Advancement in Technique, Technology and Strategy.*
 184. ! 20th Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Impella 2.5 Hemodynamic Assist Technology: Overview of Technology and Device Performance.*
 185. ! 20th Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Key Clinical Trials for 2009: High Impact Trials that Influence Clinical Practice.*
 186. ! 20th Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Carotid Artery Stent Update 2009: Under Attack...and Fighting Back!*
 187. ! 20th Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *SYNTAX in Clinical Practice: A Practical Approach to How the SYNTAX Trial Influences Clinical Decision Making.*
 188. ! 20th Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *FFR: Find and Fix it Right. Diagnostic and Therapeutic Utility of Hemodynamic Assessment.*
 189. ! American Heart Association Scientific Sessions, November 14, 2009, Orlando, FL. *Evidence Basis for Percutaneous CTO Revascularization: Insight to Procedural and Clinical Outcomes from Contemporary Trials.*
 190. ! American Heart Association Scientific Sessions and Fellows' Course, November 14, 2009, Orlando, FL. *Clinical Considerations for CTO Revascularization.*
 191. ! International Technology Exchange, November 18, 2009, Sydney, Australia. *Considerations for Complex Coronary and Peripheral Revascularization.*
 192. Scottsdale Interventional Forum, February 11, 2010, Scottsdale, AZ. *From Clinical Trials for Clinical Practice: Understanding Clinical Trials and Influence on Clinical Practice.*
 193. Scottsdale Interventional Forum, February 11, 2010, Scottsdale, AZ. *Unprotected Left Main Disease: Moving Beyond a State of Clinical Equipoise.*
 194. ! Scottsdale Interventional Forum, February 13, 2010, Scottsdale, AZ. *DES (R)evolution. 'Next Generation' DES: Evidence, Impact and Unmet Needs.*
 195. ! *Optimizing Platelet Inhibition Through All Phases of Non-ST Segment Acute Coronary Syndromes (Simultaneous Webcast).* December 17, 2009, New York, New York.
 196. ! 2010 Panvascular Summit, February 20, 2010, Salt Lake City, UT. *Who Should(n't) get a Coronary CT Angiogram? Diagnostic Challenges for a Revolutionary Technology.*
 197. Grossmont Hospital Cardiology Grand Rounds, February 17, 2010. *Antiplatelet Therapy in Non-ST Segment Elevation Acute Coronary Syndromes.*
 198. ! CRT2010, February 22, 2010, Washington, DC. *DAPT in Contemporary PCI. Risk, Benefit and Still Much to Learn.*
 199. ! CRT2010, February 23, 2010, Washington, DC. *Endeavor DES Clinical Trials Program. From Clinical Trials to Clinical Practice: Insights to Safety Outcomes.*
 200. ! CRT2010, February 23, 2010, Washington, DC. *DES (R)evolution. 'Next Generation' DES: Evidence, Impact and Unmet Needs.*

201. ! American College of Cardiology Scientific Sessions, March 15, 2010, Atlanta, GA. *Meet the Experts: Antegrade Technique in Chronic Total Occlusion Revascularization*.
202. ! *DES and Dual Antiplatelet Therapy: Current and Future Perspectives*. www.theheart.org, April 20, 2010.
203. ! China Interventional Therapeutics, Beijing, China, April 1, 2010. FDA/SFDA Clinical Trials Workshop. *A Practical Approach to Investigator-Initiated Trial Design and Performance*.
204. ! China Interventional Therapeutics, Beijing, China, April 2, 2010. *Update in Endovascular Therapies for Lower Limb Disease*.
205. ! China Interventional Therapeutics, Beijing, China, April 2, 2010. *Defining (and Redefining) the 'Optimal' Duration of Dual Antiplatelet Therapy Following DES Revascularization*.
206. ! Concepts in Contemporary Cardiovascular Medicine, April 10, 2010, Houston, TX. *DES (R)evolution: Development of Bioabsorbable Polymers and Stents in Interventional Cardiology*.
207. ! United States Food and Drug Administration, April 13, 2010, Washington, DC. *Lessons Learned From Drug-Eluting Stents in Clinical Decision Making and Trial Design*.
208. Emory Practical Intervention Course (EPIC), April 22, 2010, Atlanta, GA. *Percutaneous Revascularization for Unprotected Left Main Disease: Advancing New Standards of Care*.
209. ! Angioplasty Summit, April 27, 2010, Seoul, Korea. *Prasugrel: Studies in Risk, Benefit and the Evolution of Individualized Medicine*.
210. ! Angioplasty Summit, April 29, 2010, Seoul, Korea. *Selected Key Clinical Trials in Interventional Cardiology 2010*.
211. ! Angioplasty Summit, April 29, 2010, Seoul, Korea. *Prasugrel: Outstanding Challenges with Antiplatelet Therapy: Practicing the Art of Medicine When Science May Not Exist*.
212. ! EuroPCR 2010, June 28, 2010, Paris, France. *Case Examples in Complex Disease*.
213. *PCI in the Complex Patient*. www.theheart.org, June 29, 2010.
214. ! Duke Transradial Course, July 15, 2010, Durham, NC. *Guide Catheter Selection for Transradial Percutaneous Coronary Intervention*.
215. 2nd Transradial Catheterization Therapeutics, China Heart Congress/International Heart Forum 2010, August 13, 2010, Beijing, China. *Evidence Basis for Transradial Coronary Intervention*.
216. ! Transcatheter Therapeutics (TCT) 2010, September 22, 2010, Washington, DC. *Fundamental Responsibilities and Roles of a Principal Investigator*.
217. ! Transcatheter Therapeutics (TCT) 2010, September 22, 2010, Washington, DC. *DAPT Duration Following DES Revascularization: Practicing the Art of Medicine When the Science May Not Exist*.
218. ! Transcatheter Therapeutics (TCT) 2010, September 22, 2010, Washington, DC. *Planning a Strategy Based on the Angiogram: Fundamentals of CTO Revascularization*.
219. ! Transcatheter Therapeutics (TCT) 2010, September 23, 2010, Washington, DC. *Technical Considerations in CTO Revascularization: Nurse and Cath Lab Technician Symposium*.

220. ! Transcatheter Therapeutics (TCT) 2010, September 23, 2010, Washington, DC. *Transradial Vascular Access. Cost and Patient-related Quality of Life: Evidence Basis and Opportunity.*
221. ! Transcatheter Therapeutics (TCT) 2010, September 24, 2010, Washington, DC. *Clinical Considerations for CTO Revascularization: Revisiting Patient Selection.*
222. ! Transcatheter Therapeutics (TCT) 2010, September 25, 2010, Washington, DC. *The EXCEL Trial and Unprotected Left Main Revascularization: Lessons Learned from SYNTAX.*
223. ! Transcatheter Therapeutics (TCT) 2010, September 25, 2010, Washington, DC. *New DES Technology: Evidence, Impact and Unmet Needs.*
224. Innovations in Intervention. www.theheart.org, September 24, 2010.
225. ! Transradial Intervention: Dispelling Myths and Discussing Unresolved Issues in Transradial versus Transfemoral Catheterization. www.theheart.org, September 24, 2010.
226. ! Napa Interventional Cardiology Course, October 8, 2010, Napa, California. *Next Generation Drug-Eluting Stents.*
227. ! Napa Interventional Cardiology Course, October 8, 2010, Napa, California. *Percutaneous Revascularization for Unprotected Left Main Disease: Are We Ready for a New Standard?*
228. ! 21st Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Key Clinical Trials for 2010: High Impact Trials That Influence Clinical Decision-Making.*
229. ! 21st Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Fundamentals of Radial Artery Access: From Stick to Stich.*
230. ! 21st Annual Scripps Interventional Cardiology Course, October 15, 2010, La Jolla, California. *Retrograde Approach to Chronic Total Occlusion Revascularization: Step by Step.*
231. ! 21st Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Impella 2.5 Hemodynamic Assist Technology: Overview of Technology and Device Performance.*
232. ! 21st Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Fractional Flow Reserve Measured in Multivessel Disease: Measuring Up to a New Standard?*
233. ! American Heart Association Scientific Sessions, November 13, 2010, Chicago, IL. *In Search of the 'Best' Drug-Eluting Stent: Evidence, Impact and Unmet Needs from Comparative Trials.*
234. Transradial Interventional Program, January 15, 2011, Philadelphia, PA. *Transradial and Transfemoral Vascular Closure: Is There a Clinically Meaningful Difference?*
235. ! 8th Annual Transcatheter Therapeutics Left Main and CTO Summit, February 15, 2011, New York, New York. *Unprotected Left Main Percutaneous Revascularization in Acute Myocardial Infarction.*
236. ! 8th Annual Transcatheter Therapeutics Left Main and CTO Summit, February 15, 2011, New York, New York. *Clinical Trials and Outcomes with Drug-Eluting Stents in Chronic Total Occlusion Revascularization: Redefining and Refining Standards of Treatment.*
237. ! Cardiovascular Revascularization Therapies, February 27, 2011, Washington, DC. *Drug-Eluting Stents for Chronic Total Occlusion Revascularization.*

238. ! Cardiovascular Revascularization Therapies, February 28, 2011, Washington, DC. *Dual Antiplatelet Therapy: 6 Months, 12 months, 3 years? A 'Rational' Discussion for a Patient Focused Approach.*
239. ! Cardiovascular Revascularization Therapies, February 28, 2011, Washington, DC. *Drug-Eluting Stents Revascularization for Erectile Dysfunction.*
240. ! Cardiovascular Revascularization Therapies, February 28, 2011, Washington, DC. *VANTAGE 1: First in Human Evaluation of the Cintra Corolimus-Eluting Stent System.*
241. ! China Interventional Therapeutics, March 17, 2011, Beijing, China. *In Search of the 'Best' Drug-Eluting Stent: Evidence, Impact and Unmet Needs from Contemporary Trials.*
242. ! China Interventional Therapeutics, March 17, 2011, Beijing, China. *ENDEAVOR and RESOLUTE DES Programs: From Clinical Trials to Clinical Practice.*
243. ! China Interventional Therapeutics, March 17, 2011, Beijing, China. *An Evidence-Based Rationale for Transradial Percutaneous Revascularization.*
244. ! China Interventional Therapeutics, March 17, 2011, Beijing, China. *Opportunities for Intervention: Emerging Technology and Indications for Treatment of Peripheral Arterial Disease*
245. ! American College of Cardiology Scientific Sessions and I2 Summit, April 2, 2011, New Orleans, LA. *Unprotected Left Main Revascularization. Are We Ready for a New Standard?*
246. ! American College of Cardiology Scientific Sessions and I2 Summit, April 2, 2011, New Orleans, LA. *DILEMMA: Decisions In Unprotected Left Main Management.*
247. ! American College of Cardiology Scientific Sessions and I2 Summit, April 3, 2011, New Orleans, LA. *Evidence Basis for Unprotected Left Main Percutaneous Revascularization.*
248. ! American College of Cardiology Scientific Sessions and I2 Summit, April 4, 2011, New Orleans, LA. *Emerging Indications for Endovascular Intervention: Erectile Dysfunction.*
249. ! *The Cardiology Show: American College of Cardiology Scientific Sessions and I2 Summit, April 5, 2011, www.theheart.org.*
250. ! National Cardiovascular Controversies, April 14, 2011, Lake Oconee, Georgia. *Complex Coronary Percutaneous Revascularization: Advancing Standards in Comparison with Surgery.*
251. ! National Cardiovascular Controversies, April 14, 2011, Lake Oconee, Georgia. *PCI for Multivessel Disease: A Practical Approach to How the SYNTAX Score Influences Clinical Decision-Making.*
252. Angioplasty Summit TCT Asia Pacific, April 27, 2011, Seoul, Korea. *Sirolimus-Eluting Stents Revisited: Unexpected Results and Clinical Implications from BASKET PROVE, SORT OUT IV, EXCELLENT and ISAR TEST 4.*
253. Angioplasty Summit TCT Asia Pacific, April 27, 2011, Seoul, Korea. *Current and Future Stent Designs for Drug-Eluting Stents.*
254. ! Angioplasty Summit TCT Asia Pacific, April 28, 2011, Seoul, Korea. *A Global Perspective of Catheter-Based Therapies.*
255. Angioplasty Summit TCT Asia Pacific, April 28, 2011, Seoul, Korea. *Platelet Function Testing and Outcomes.*
256. ! Angioplasty Summit TCT Asia Pacific, April 28, 2011, Seoul, Korea. *The Science of Future Workhorse Drug-Eluting Stents.*

257. Angioplasty Summit TCT Asia Pacific, April 29, 2011, Seoul, Korea. *Complex Coronary Intervention: Challenges of Antegrade Chronic Total Occlusion Revascularization.*
258. ! Hong Kong Cardiology of Cardiology Annual Scientific Sessions, April 30, 2011, Hong Kong. *Unmet Needs in Cardiovascular Medicine: Future Directions for Interventional Cardiology.*
259. ! Hong Kong Cardiology of Cardiology Annual Scientific Sessions, April 30, 2011, Hong Kong. *Making Complex Simple: Advances in DES Technology and Trial Design.*
260. ! Society for Coronary Angiography and Interventions (SCAI) 2011 Annual Sessions, May 4, 2011, Baltimore, MD. *New Frontiers in Cardiovascular Medicine: Future of Drug-Eluting Stents.*
261. ! Society for Coronary Angiography and Interventions (SCAI) 2011 Annual Sessions, May 4, 2011, Baltimore, MD. *Percutaneous Revascularization for Unprotected Left Main Disease: Evidence Basis.*
262. ! *The Bob Harrington Show: Occluded Artery Trial and Revascularization of Total Occlusions.* www.theheart.org, July 22, 2011.
263. ! Complex Interventional Cardiovascular Therapy 2011, July 30, 2011, San Francisco, CA. *Percutaneous Revascularization for Erectile Dysfunction: Evidence, Case-Based Demonstration and Future Directions.*
264. ! China Heart Congress 2011, August 13, 2011, Beijing, China. *Evidence Basis For Transradial Percutaneous Coronary Intervention: Contemporary Evidence and Opportunities for Advancement.*
265. ! 22nd Annual Scripps Clinic Coronary Interventions, September 21, 2011, San Diego, CA. *Impella 2.5 Hemodynamic Assist Technology: Technology Overview, Utilization Technique and Expanding Indications.*
266. ! 22nd Annual Scripps Clinic Coronary Interventions, September 22, 2011, San Diego, CA. *Key Clinical Trials: Impact Trials that Influence Clinical Practice.*
267. ! 22nd Annual Scripps Clinic Coronary Interventions, September 22, 2011, San Diego, CA. *The Inverse of Can't: Complex Transradial Intervention.*
268. ! 22nd Annual Scripps Clinic Coronary Interventions, September 23, 2011, San Diego, CA. *Antegrade Chronic Total Occlusion Revascularization.*
269. International Technology Exchange, October 6, 2011, Sydney, Australia. *An International Perspective on Coronary Revascularization: Evidence, Impact and Unmet Needs.*
270. International Technology Exchange, October 6, 2011, Sydney, Australia. *DES Revolution, Steps Forward or Sideways?*
271. ! Duke Advanced Course in Transradial Angiography and Intervention, October 20-22, 2011, Durham, NC. *The Inverse of Can't: Transradial Bifurcation and Chronic Total Occlusion Revascularization.*
272. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. *Renal Denervation and the SYMPPLICITY HTN 3 Trial.*
273. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. *ENDEAVOR IV: 5-Year Final Outcomes.*
274. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. *Endeavor Zotarolimus-Eluting Stent Program: From Clinical Trials to Clinical Practice.*
275. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. *Self-Assessment Course, Complex Lesions: Bifurcations and Chronic Total Occlusions.*

276. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Industry Sponsored Research: Challenges and Opportunities.
277. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Left Main In-Stent Restenosis: A Cautionary Tale.
278. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Revascularization Strategies for Left Main and Multivessel Coronary Disease: A Practical Approach Amidst the Complexities of Clinical Decision-Making.
279. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Coronary Stent Fracture. Does it Still Happen? Do we care?
280. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. CTO Toolbox and Technique: Microcatheters, Support Catheters and Stents.
281. ! 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. *Live Case Demonstrations from Piedmont Heart Institute, Atlanta, GA.*
282. ! Complex Lesion Case Series: Fractional Flow Reserve and Multivessel Coronary Disease. www.theheart.org, November 8, 2011.
283. ! Making Same Day Discharge a Reality. www.theheart.org, November 9, 2011.
284. ! 2011 American Heart Association Scientific Sessions, November 15, 2011, Orlando, FL. Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY III Trial.
285. ! 4th Annual Puerto Rican Society of Interventional Cardiology Meeting, December 4, 2011, San Juan, PR. *The Future of Interventional Cardiology: Evidence, Impact and Unmet Needs.*
286. ! 4th Annual Puerto Rican Society of Interventional Cardiology Meeting, December 4, 2011, San Juan, PR. *Contemporary Chronic Total Occlusion Revascularization.*
287. ! Society of Thoracic Surgeons Annual Scientific Sessions, January 30, 2012, Fort Lauderdale, FL. *Advances in Drug-Eluting Coronary Stents: Opportunities for Evidence and Evolution.*
288. ! Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Clinical Trials and Outcomes with Drug-Eluting Stents in Chronic Total Occlusion Revascularization.*
289. ! Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Catheter-Based Renal Denervation for Resistant Hypertension: Therapeutic Options for Those Previously Without Alternative.*
290. ! Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Advanced Generation Drug-Eluting Stents: Evidence, Impact and Unmet Needs From Comparative Trials.*
291. ! Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Coronary Perforation: Management Issues.*
292. ! Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Advanced Methods for Guiding Catheter Support: Expecting and Overcoming Challenges in Chronic Total Occlusion Revascularization.*
293. Scottsdale Interventional Forum 2012, February 17, 2012, Scottsdale, AZ. *Hemodynamic Support in Acute Myocardial Infarction.*

294. Scottsdale Interventional Forum 2012, February 17, 2012, Scottsdale, AZ. *Chronic Total Occlusion Revascularization: Strategy and Technique.*
295. Scottsdale Interventional Forum 2012, February 17, 2012, Scottsdale, AZ. *Intravascular Ultrasound Imaging in Left Main Percutaneous Revascularization: Measuring Up to New Standards.*
296. ! Complex Coronary Interventions: 10th Annual Left Main and CTO Summit, February 23, 2012, New York, NY. *Left Main Percutaneous Revascularization: The Year in Review and What is to Come.*
297. ! Complex Coronary Interventions: 10th Annual Left Main and CTO Summit, February 23, 2012, New York, NY. *1 versus 2 Stent Revascularization Strategies for Left Main Disease: A Practical and Evidence Oriented Approach to Clinical Decision-Making.*
298. ! Complex Coronary Interventions: 10th Annual Left Main and CTO Summit, February 24, 2012, New York, NY. *Angiographic and Clinical Surveillance Following Left Main Percutaneous Revascularization: Is It Worth Taking a Look?*
299. ! Complex Coronary Interventions: 10th Annual Left Main and CTO Summit, February 25, 2012, New York, NY. *Live Case Demonstrations from Piedmont Heart Institute, Atlanta, GA.*
300. ! Interventional Cardiology 2012: 27th Annual International Symposium, March 4-9, 2012, Snowmass, Colorado. *Catheter-based Renal Denervation: Design and Rationale of the SYMPLCITY HTN-3 Trial.*
301. ! Interventional Cardiology 2012: 27th Annual International Symposium, March 4-9, 2012, Snowmass, Colorado. *Emerging Indications for Endovascular Therapies: Erectile Dysfunction.*
302. China Interventional Therapeutics, February 2012, Beijing, China. *Percutaneous Left Main Revascularization: A Perspective from The United States.*
303. China Interventional Therapeutics, February 2012, Beijing, China. *Endeavor and Resolute Zotarolimus-Eluting Stent Programs.*
304. China Interventional Therapeutics, February 2012, Beijing, China. *Resolute Drug Eluting Stent Program.*
305. ! American College of Cardiology Scientific Sessions, March 25, 2012, Chicago, IL. *The Inverse of Can't and Won't: An Evidence- and Practice-Based Rationale for Transradial Coronary Intervention.*
306. ! American College of Cardiology Scientific Sessions, March 25, 2012, Chicago, IL. *Revascularization Strategies for Left Main and Multivessel Disease: A Practical Approach Amidst the Complexities of Clinical Decision Making.*
307. ! American College of Cardiology Scientific Sessions, March 25, 2012, Chicago, IL. *Complex Coronary Revascularization: A Year in Review.*
308. ! American College of Cardiology Scientific Sessions, March 24, 2012, Chicago, IL. *Percutaneous Left Main Revascularization: Evidence for Clinical Decision Making and Guidelines.*
309. ! American College of Cardiology Scientific Sessions, March 24, 2012, Chicago, IL. *Percutaneous Left Main Revascularization: Evolution of Method and Evidence.*
310. Atlanta Academy of Institutional Pharmacy, April 19, 2012, Atlanta, GA. *The Art and Science of Clinical Decision Making for Antiplatelet Therapy: Studies in Risk, Benefit and the Evolution of Individualized Medicine.*
311. ! 18th Annual Interventional Cardiology Fellows Course, April 21, 2012, Miami, FL. *The Endeavor and Resolute Zotarolimus-Eluting Stent Programs.*

312. ! 18th Annual Interventional Cardiology Fellows Course, April 22, 2012, Miami, FL. *Chronic Total Occlusion Revascularization.*
313. ! Angioplasty Summit/ TCT Asia, April 26, 2012, Seoul, Korea. *What is the final goal of transcatheter renal denervation?*
314. ! Angioplasty Summit/ TCT Asia, April 26, 2012, Seoul, Korea. *Catheter-based renal denervation for hypertension and other areas of research.*
315. ! Angioplasty Summit/ TCT Asia, April 26, 2012, Seoul, Korea. *Application of renal denervation to treatment of chronic heart failure.*
316. Piedmont Heart Institute, Cardiology Grand Rounds, May 9, 2012. *Catheter-based renal denervation for uncontrolled hypertension.*
317. ! Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Unprotected left main revascularization: evolution of science and method.*
318. ! Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Longitudinal stent distortion: the intersection of design and technique.*
319. ! Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Catheter-based renal denervation for resistant hypertension: therapeutic alternatives for those previously without option.*
320. ! Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Left main percutaneous revascularization: an interventional perspective of advances in science and method.*
321. ! Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Economic outcomes associated with complex percutaneous revascularization: the cost of chronic total occlusion revascularization.*
322. ! Society of Coronary Angiography and Interventions (SCAI) Women in Innovations (WIN) Program, September 24, 2012, Washington, DC. *ENDEAVOR zotarolimus-eluting stent program angiographic and clinical outcomes for women with symptomatic coronary artery disease.*
323. ! Evolution of Stent Design and Optimizing Percutaneous Coronary Intervention, www.theheart.org, October 22, 2012.
324. ! From Good to Great: Improving the Economics of PCI Outcomes, www.theheart.org, October 23, 2012.
325. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Industry-sponsored versus investigator-initiated research: similarities, differences and pathways to success.*
326. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Left main bifurcation stenting: highlights from the past 12 months.*
327. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Rationale and data for different DAPT durations: from 3 months to 30 months or longer.*
328. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *15th annual interventional cardiology board review course: bifurcations and chronic total occlusions.*
329. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *SYMPPLICITY HTN-3 trial design and current status.*
330. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *DESSOLVE II: a prospective, randomized trial of biodegradable polymer-based sirolimus-eluting stent versus a zotarolimus-eluting stent.*

331. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Live case transmissions from Piedmont Heart, Atlanta, GA.*
332. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *FDA Town Hall meeting: An objective performance criterion model for "standard" drug-eluting stent approval.*
333. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Chronic total occlusion guidewire design and selection: antegrade and retrograde approaches.*
334. ! 8th Transradial Intervention Course, November 3, 2012, Ahmedabad, India. *Transradial unprotected left main coronary revascularization.*
335. ! Piedmont Healthcare Internal Medicine Grand Rounds, November 7, 2012, Atlanta, GA. *Renal Denervation Therapy for Resistant Hypertension and Sympathetic-mediated Disease Conditions.*
336. ! 7th Annual International Technology Exchange, November 16, 2012, Sydney, Australia. *Realizing the Real Benefit of PCI: Applying Effective Therapy to Identify Those Who Benefit Most.*
337. ! Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Chronic Total Occlusion Revascularization 2013: Evolution of Strategy and Technique.*
338. ! Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Algorithm and Tools for the Uncrossable Chronic Total Occlusion.*
339. ! Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Coronary perforation in Chronic Total Occlusion Revascularization: Management Issues.*
340. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Controlled Antegrade and Retrograde Tracking with Snaring of Retrograde Guidewire.*
341. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Percutaneous Chronic Total Occlusion Revascularization: Modeling a High Volume, Clinically Successful Program.*
342. ! ISET 2013, January 21, 2013, Miami, FL. *Catheter-based Renal Denervation for Resistant Hypertension. Therapeutic Options for Those Previously Without Alternative.*
343. ! ISET 2013, January 21, 2013, Miami, FL. *Catheter-based Renal Denervation for Resistant Hypertension. Evolution of Evidence and Technology.*
344. Marquis Lecture, Scottsdale Interventional Forum, February 14, 2013. *Left Main Revascularization: An Interventional Perspective on Advances in Science and Method.*
345. ! 10th Annual Left Main and Chronic Total Occlusion Summit, February 23, 2013, New York, New York. *Live Case Operator, Piedmont Heart Institute.*
346. ! CRT 2013, February 26, 2013, Washington, DC. *PCI Appropriateness Criteria. We Can Do Better.*
347. ! CRT 2013, February 26, 2013, Washington, DC. *Ventricular Assist Devices and Regulatory Challenges: An Academic View.*
348. ! CRT 2013, February 26, 2013, Washington, DC. *Clinical Trial Design Considerations for Moderate and Resistant Hypertension.*
349. ! CRT 2013, February 26, 2013, Washington, DC. *Clinical Trial Design Considerations for Moderate and Resistant Hypertension.*

350. ! CRT 2013, February 26, 2013, Washington, DC. *Catheter-based Renal Denervation with the SYMPLICITY System Provides Safe and Durable Blood Pressure Reduction out to Three Years.*
351. ! American College of Cardiology, March 9, 2013, San Francisco, CA. *Left Main Revascularization: Perspective on Advances in Method, Outcome and Clinical Decision Making.*
352. American College of Cardiology, March 10, 2013, San Francisco, CA. *Debate: DES Revolution: Bioresorbable Stents Will Only Maintain a Niche Indication.*
353. American College of Cardiology, March 9, 2013, San Francisco, CA. *Chronic Total Occlusion Revascularization: Remove CTOs from Appropriateness Use Criteria.*
354. ! American College of Cardiology, March 9, 2013, San Francisco, CA. *CTO Percutaneous Revascularization: All the Reasons You Should Do It, and There Has Never Been a Better Time to Learn.*
355. American College of Cardiology, March 9, 2013, San Francisco, CA. *Algorithm and Tools for The Uncrossable CTO.*
356. ! American College of Cardiology, March 9, 2013, San Francisco, CA. *Post Acute Myocardial Infarction Risk for Sudden Death: Incidence, Predictors and Strategies to Reduce Risk.*
357. ! China Interventional Therapeutics, March 21, 2013, Beijing, China. *Renal Denervation Therapy with the SYMPLICITY System and Clinical Trial Program.*
358. China Interventional Therapeutics, March 21, 2013, Beijing, China. *Chronic Total Occlusion Revascularization in 2013: Evolution of Strategy and Technique.*
359. China Interventional Therapeutics, March 22, 2013, Beijing, China. *Chronic Total Occlusion Revascularization in 2013: What You Need to Know.*
360. ! China Interventional Therapeutics, March 22, 2013, Beijing, China. *ACC at CIT: Dual Antiplatelet Therapy and Drug Eluting Stents.*
361. China Interventional Therapeutics, March 22, 2013, Beijing, China. *Complex Left Main and Multivessel Disease. Live case operator.*
362. ! Japanese Circulation Society, March 28, 2013, Tokyo, Japan. *Enrollment Strategies and Technique for Renal Denervation Therapy.*
363. 19th Annual Interventional Fellows Course, April 16, 2013, San Jose, CA. *Overview of Chronic Total Occlusion Revascularization.*
364. Piedmont Cardiology Napa Valley 2013, April 18, 2013, Napa, CA. *Unprotected Left Main and Multivessel Coronary Revascularization Strategies.*
365. ! Piedmont Cardiology Napa Valley 2013, April 18, 2013, Napa, CA. *Renal Denervation Therapy for Resistant Hypertension.*
366. Piedmont Cardiology Napa Valley 2013, April 18, 2013, Napa, CA. *Advances in Lower Limb Revascularization for Intermittent Claudication and Critical Limb Ischemia.*
367. ! SCAI 2013, May 9, 2013, Orlando, FL. *Left Main Coronary Revascularization: Perspective on Method, Outcome and Clinical Decision Making.*
368. ! EuroPCR 2013, May 21, 2013, Paris, France. *Stent Conformation and Impact on Clinical Outcome: Intersection of Design and Technique.*
369. ! EuroPCR 2013, May 21, 2013, Paris, France. *SYMPLICITY Trial Clinical Program Overview.*
370. ! www.theheart.org. May 21, 2013. *Dual Antiplatelet Therapy Following Percutaneous Revascularization: An International Perspective.*

371. ! www.theheart.org. May 21, 2013. *Renal Denervation Therapy for Resistant Hypertension: An International Perspective.*
372. ! NYC TRAC Transradial Course, June 28, 2013, New York. *Why the Radial Now in the United States? Clinical, Economic and Quality of Life Incentives.*
373. SIRIUS Radio, July 3, 2013. *Heart to Heart with Dr. Fred Feit.*
374. ! 15th Annual Cardiovascular Symposium, September 7, 2013, San Bernadino, CA. *Physiologic Rationale for Interventional Therapies in Hypertension. Renal Artery Denervation: The Novel Therapy for the Resistant Hypertension.*
375. ! 24th Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Transradial Intervention and Guide Catheter Selection: Procedure with a Purpose.*
376. ! 24th Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Key Clinical Trials 2013: Impact Trials that Influence Clinical Practice.*
377. ! 24th Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Stent Structure and Impact on Procedural and Clinical Outcomes.*
378. ! 24th Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Percutaneous CTO Revascularization: Modeling a High Volume, Clinically Successful Program.*
379. ! 24th Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Chronic Total Occlusion Revascularization 2013: Evolution of Strategy and Technique.*
380. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *Device and Clinical Trial Update: SYMPLICITY and SPYRAL for Renal Denervation.*
381. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *Moderate Resistant Hypertension: A New Indication for Renal Artery Denervation?*
382. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *The Evolution from Endeavor to Resolute: Stent Design Considerations and Results.*
383. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *The Masters' Solutions: Complex Left Main Trifurcation Disease.*
384. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *First-in-human experience with a novel high-flow percutaneous heart pump.*
385. ! Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *Live case operator, chronic total occlusion cases from Piedmont Hospital, Atlanta, GA.*
386. ! American Heart Association Scientific Sessions, November 18, 2013, Dallas, TX. *Complex Transradial Percutaneous Coronary Revascularization.*
387. ! American Heart Association Scientific Sessions, November 18, 2013, Dallas, TX. *Chronic Total Occlusion Revascularization: Advances in Strategy and Technique.*
388. ! 11th Annual Left Main and Chronic Total Occlusion Summit, February 2013, New York, New York. *Left Main Trifurcation Disease.*
389. ! CRT 2014, February 2014, Washington, DC. *Renal Denervation Trial Considerations for Moderate Hypertension.*

390. China Interventional Therapeutics 2014, March 2014, Shanghai, China. *Back to the Basics for Bifurcations: Angiography Alone is All that is Needed.*
391. China Interventional Therapeutics 2014, March 2014, Shanghai, China. *Perspectives on Renal Denervation: Opportunity or End, What's Next.*
392. China Interventional Therapeutics 2014, March 2014, Shanghai, China. *Evolution from Endeavor to Resolute: Stent Design Considerations and Results.*
393. American College of Cardiology Scientific Sessions, March 2014. *Pharmacodynamic considerations and clinical impact of dual antiplatelet therapy interruption after Resolute zotarolimus-eluting stent implantation.*
394. ! American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Fellows' Course: Bifurcation, Ostial and Left Main Disease: Perspectives on Advances in Method, Outcome and Clinical Decision Making.*
395. ! American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Transradial Primary PCI: Accents, Access, Evidence and Good Common Sense.*
396. ! American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Left Main Percutaneous Revascularization.*
397. ! American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Safety and Effectiveness of Xience Drug-Eluting Stents in Chronic Total Occlusion Revascularization: Results from the EXPERT CTO Multicenter Clinical Trial.*
398. ! American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *SYMPPLICITY HTN-3: An In-depth Discussion Regarding Trial Results and the Future of Renal Denervation, www.tctmd.com*
399. TCTAP 19th Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Non-Hypertension Indications for Renal Denervation Therapy.*
400. ! TCTAP 19th Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Left Main Revascularization and the EXCEL Clinical Trial.*
401. TCTAP 19th Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Principal Results from the SYMPPLICITY HTN 3 Trial and Global Symplivity Registry.*
402. ! TCTAP 19th Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Live case operator, unprotected left main disease.*
403. TCTAP 19th Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Renal Denervation Beyond SYMPPLICITY HTN 3: Next Steps.*
404. ! EuroPCR, May 21, 2014, Paris, France. *Sudden cardiac death in post-acute myocardial infarction and post-revascularization patients. Who is at risk?*
405. ! EuroPCR, May 22, 2014, Paris, France. *Hotline Session: SYMPPLICITY HTN3: Subgroup Analyses of Predictors of Blood Pressure Response*
406. ! *Navigating the Maze of SYMPPLICITY HTN 3.* May 21, 2014, Paris, France. www.theheart.org.
407. ! American Society of Hypertension/ Food and Drug Administration Think Tank Meeting. *Procedural considerations for renal denervation.* June 26, 2014. Washington, DC.
408. ! *PCI Master Class: Complex PCI -- Deconstructing the Tools of the Trade.* July 31, 2014. www.theheart.org.
409. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Dual Antiplatelet Therapy Following Percutaneous Revascularization: A Case Study.*

410. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Transradial Primary Percutaneous Intervention: Access and Evidence.*
411. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Perspectives on Same Day Discharge: Once Nice to Have, Now Essential.*
412. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Left Main Anatomy and Consequences.*
413. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Renal Denervation, Not So Simple: Still Afloat, Not Dead in the Water.*
414. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *HeartMate Percutaneous Heart Pump: A Novel High Flow Circulatory Support Catheter.*
415. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Renal Denervation for Hypertension: Overview of Clinical Trials and Next Steps.*
416. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Primary Endpoint Results from the PROMUS Element Plus US Post-Approval Study (PE-Plus PAS): 1-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent.*
417. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Bifurcation PCI with Physiologic Guidance: Crossroads for Clinical Decision Making.*
418. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *SYMPPLICITY HTN 3 Trial: Mechanistic Insights to Blood Pressure Response.*
419. ! SCAI Transradial Interventional Program (TRIP), Atlanta, GA, January 24, 2015. *From the Wrist to the Coronaries: Overcoming Challenges of Catheter Advancement and Positioning.*
420. ! SCAI Transradial Interventional Program (TRIP), Atlanta, GA, January 24, 2015. *Balancing Costs with Quality in PCI.*
421. ! SCAI Transradial Interventional Program (TRIP), Atlanta, GA, January 24, 2015. *Complications with Transradial Catheterization.*
422. ! CRT2015, Washington, DC, February 22-24, 2015. *SYMPPLICITY HTN 3 Trial: Subgroup Analyses.*
423. ! CRT2015, Washington, DC, February 22-24, 2015. *Renal Denervation for Moderate Hypertension: The Spyral Clinical Trial Program.*
424. ! CRT2015, Washington, DC, February 22-24, 2015. *Uncommon Complications in Chronic Total Occlusion Percutaneous Coronary Intervention and Management.*
425. Chronic Total Occlusion Summit, New York, February 25, 2015. *Contemporary Outcomes with Chronic Total Occlusion Revascularization.*
426. ! Chronic Total Occlusion Summit, New York, February 25, 2015. *Chronic Total Occlusion Revascularization 2015: Need for Advanced Training and Technique.*
427. ! American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Left Main Anatomy and Consequences.*
428. ! American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *The Heart Team Approach: A 'Disruptive' Strategy.*

429. ! American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Evolution of DES Trials: Studies with Novel Bioresorbable and Permanent Polymer DES.*
430. ! American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Post AMI Risk for Sudden Cardiac Death: Incidence, Predictors and Strategies to Reduce Risk.*
431. ! American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *DAPT Duration in Contemporary PCI: Practicing the Art of Medicine with Limited Science.*
432. ! American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Fellows' Bootcamp: Overcoming Challenges in Transradial Cardiac Catheterization.*
433. ! China Interventional Therapeutics, Beijing, March 20-21, 2015. *Live case operator.*
434. ! China Interventional Therapeutics, Beijing, March 20-21, 2015. *Updates from SYMPPLICITY HTN-3: What We Know and What We Have Learned.*
435. ! China Interventional Therapeutics, Beijing, March 20-21, 2015. *Advanced Training and Specialization for CTO Practitioners.*
436. ! China Interventional Therapeutics, Beijing, March 20-21, 2015. *Debate: Prolonged DAPT Is Mandatory after Stenting.*
437. ! ACC 2015 For Interventional Cardiology: TOTAL, MATRIX, DANAMI. March 26, 2015. www.medscape.com.
438. ! Latin American Technology and Therapy Exchange. *Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention 2015.* April 9, 2015, Montevideo, Uruguay.
439. ! Latin American Technology and Therapy Exchange. *Renal Denervation: Next Steps.* April 9, 2015, Montevideo, Uruguay.
440. ! Latin American Technology and Therapy Exchange. *Chronic Total Occlusion Strategy and Method.* April 10, 2015, Montevideo, Uruguay.
441. ! Latin American Technology and Therapy Exchange. *Bioresorbable Scaffolding: Debate.* April 9, 2015, Montevideo, Uruguay.
442. ! EuroPCR 2015 Scientific Sessions. *Renal Denervation and Evolution of Science and Technique: Mechanistic Insights to Blood Pressure Response, Subgroup Analyses and Future Directions.* May 20, 2015, Paris, France.
443. ! EuroPCR 2015 Scientific Sessions. *Spyral HTN: Considerations for Trial Design in Moderate Hypertension.* May 20, 2015, Paris, France.
444. ! EuroPCR 2015 Scientific Sessions. *Renal Denervation, Back to the Future.* May 20, 2015, www.medscape.com
445. ! Piedmont Napa Valley Cardiology Conference. *Completeness of Revascularization: Beneficial, Practical, Achievable?* June 5, 2015, Napa, California.
446. ! Piedmont Napa Valley Cardiology Conference. *Renal Denervation Next Steps.* June 5, 2015, Napa, California.
447. ! C3 Complex Coronary Interventions. *Antegrade Bailout Chronic Total Occlusion Coronary Intervention.* June 10, 2015, Orlando, FL.
448. ! American College of Cardiology, North and South Carolina Chapters, 22nd Annual Joint Meeting. *Antiplatelet Therapy, Point/Counterpoint.* September 26, 2015, Pinehurst, NC.
449. ! Pacific Northwest Cardiovascular Summit. *Renal Denervation Next Steps: Evolution of Evidence and Future Directions.* October 3, 2015, Portland, OR.

450. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. Live case demonstrations, live case operator. October 12, 2015, San Francisco, CA.
451. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. *Two-Year Outcomes of the Promus Element Post Approval Study*. October 13, 2015, San Francisco, CA.
452. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. *Renal Denervation Therapies: Current State of Evidence*. October 14, 2015, San Francisco, CA.
453. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. *Advanced Stent Designs and Technologies: What's Coming to the USA?* October 14, 2015, San Francisco, CA.
454. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. *Temporary Cardiac Support and High Risk PCI: SHIELD II Study*. October 2015, San Francisco, CA.
455. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. *Left Main Percutaneous Revascularization: Overview of 2 Stent Techniques*. October 15, 2015, San Francisco, CA.
456. ! Transcatheter Therapeutics Scientific Sessions (TCT) 2015. *You Can't Do That Radially: I Just Did!* October 15, 2015, San Francisco, CA.
457. ! Scripps Interventions Course 2015. *Chronic total occlusion revascularization 2015. Evolution of antegrade technique and strategy*. October 28-30, 2015.
458. ! Scripps Interventions Course 2015. *Key clinical trials 2015. Impact trials that influence clinical practice*. October 28-30, 2015.
459. ! Scripps Interventions Course 2015. *Synergy stent as a model DES in clinical trials and practice*. October 28-30, 2015.
460. ! VIVA 2015. *Renal denervation next steps: mechanistic insights to blood pressure response, expansion to new indications and future directions*. November 2, 2015. Las Vegas, NV.
461. ! International Conference for Innovations (ICI) 2015. *Renal denervation for hypertension: evidence and future directions*. December 14, 2015. Tel Aviv, Israel.
462. ! International Conference for Innovations (ICI) 2015. *Medinol BioNir drug-eluting stent program*. December 14, 2015. Tel Aviv, Israel.
463. ! CRF TRAC Program. *Catheter selection and tricks for successful angiography*. January 30, 2016, Atlanta, GA.
464. ! CRF TRAC Program. *Radial approach for peripheral procedures*. January 30, 2016, Atlanta, GA.
465. ! Piedmont Hospital Grand Rounds. *Renal denervation therapy for hypertension*. February 10, 2016. Atlanta, GA.
466. ! CRT 2016. *The Micell MiStent drug-eluting stent program*. February 22, 2016. Washington, DC.
467. ! CRT 2016. *Why I am still excited about renal denervation after SYMPPLICITY HTN 3*. February 22, 2016. Washington, DC.
468. ! CRT 2016. *Optimal design for evaluation of renal denervation devices: an academic perspective*. February 22, 2016. Washington, DC.
469. ! FICCRIO 2016, Forum for Complex Coronary Intervention. *Complex coronary intervention and completeness of revascularization*. March 4, 2016. Rio de Janeiro, Brasil.

470. ! FICCRIO 2016, Forum for Complex Coronary Intervention. March 4, 2016. *Bifurcation anatomy and consequences: the left main example*. Rio de Janeiro, Brasil.
471. ! FICCRIO 2016, Forum for Complex Coronary Intervention. *Chronic total occlusion revascularization: evolution of evidence and technique*. March 4, 2016. Rio de Janeiro, Brasil.
472. ! China Interventional Therapeutics 2016 Scientific Sessions. *CTO PCI: the modern approach*. March 18, 2016. Beijing, China.
473. ! China Interventional Therapeutics 2016 Scientific Sessions. *Current perspectives on DES outcomes: why we need to continue development of next generation DES systems*. March 19, 2016. Beijing, China.
474. ! China Interventional Therapeutics 2016 Scientific Sessions. *Live case operator*. March 19, 2016. Beijing, China.
475. ! China Interventional Therapeutics 2016 Scientific Sessions. *Renal denervation update: what we know, and what we have learned*. March 19, 2016. Beijing, China.
476. ! American College of Cardiology Scientific Sessions. *Left main/multivessel revascularization: how to do it reliably and durably*. April 2, 2016. Chicago, Illinois.
477. ! American College of Cardiology Scientific Sessions. *Moderator, ACC i2 Live case transmissions*. April 3, 2016. Chicago, Illinois.
478. ! American College of Cardiology Scientific Sessions. *Have we made another leap forward with newest generation bioabsorbable polymer and fully bioresorbable drug-eluting stents? Yes, the newest drug-eluting stents clearly surpass current generation durable polymer DES*. April 3, 2016. Chicago, Illinois.
479. ! American College of Cardiology Scientific Sessions. *Bioabsorbable polymer DES in current practice: how do we apply the results of the clinical trials?* April 3, 2016. Chicago, Illinois.
480. ! American College of Cardiology Scientific Sessions. *Role of coronary imaging in CTO intervention*. April 4, 2016. Chicago, Illinois.
481. ! American College of Cardiology Scientific Sessions. *Fellows' Bootcamp: unprotected left main and bifurcation disease*. April 4, 2016.
482. ! www.medscape.org, April 29, 2016. *Sprinting to Better Blood Pressure Control: Consider All the Options*.
483. ! TCTAP 2016. *Bioresorbable polymer DES in high risk patients*. April 28, 2016. Seoul, Korea.
484. ! TCTAP 2016. *Left main percutaneous revascularization: which technique, and which stents?* April 28, 2016. Seoul, Korea.
485. ! SCAI Scientific Sessions. *Orbital atherectomy: device overview and clinical applications*. May 5, 2016. Orlando, FL.
486. ! SCAI Scientific Sessions. *Renal denervation next steps: considerations for clinical design and conduct*. May 5, 2016. Orlando, FL.
487. ! Taiwan Society of Cardiology 46th Annual Convention and Scientific Session. *Live case operator, chronic total occlusions*. May 14, 2016. Taipei, Taiwan.
488. ! Taiwan Society of Cardiology 46th Annual Convention and Scientific Session. *Renal Denervation: Next Steps for Clinical Trial Design and Conduct*. May 14, 2016. Taipei, Taiwan.
489. ! Taiwan Society of Cardiology 46th Annual Convention and Scientific Session. *Device Therapies for Hypertension*. May 14, 2016. Taipei, Taiwan.

490. ! EuroPCR 2016. *The global SYMPLICITY Spyral program*. May 18, 2016. Paris, France.
491. ! EuroPCR 2016. *Individualized treatment decisions and novel technology in complex PCI*. May 18, 2016. Paris, France.
492. ! Piedmont Napa Valley Cardiology Conference. *Renal Denervation: Evolution of Evidence and Next Steps*. June 2, 2016, Napa, California.
493. ! Piedmont Napa Valley Cardiology Conference. *Culprit and Non-Culprit PCI in Acute Myocardial Infarction*. June 3, 2016, Napa, California.
494. ! New York University Langone Medical Center, Cardiology Grand Rounds and Visiting Professor. *Renal Denervation Next Steps: Evolution of Evidence and Future Directions*. June 17, 2016, New York, New York.
495. ! Complex Cardiovascular Catheter Therapeutics. *Bioresorbable Polymer Drug Eluting Stents*. June 29, 2016, Orlando, FL.
496. ! 2016 Geoffrey Hartzler Interventional Cardiology Symposium. *Complex Coronary Intervention: Left Main Disease and Chronic Total Occlusion*. July 11-13, 2016, Wailea, Maui.
497. ! 2016 Geoffrey Hartzler Interventional Cardiology Symposium. *Complex Higher Risk and Indicated Patients: Low Ejection Fraction, Multivessel Disease and Chronic Total Occlusion*. July 11-13, 2016, Wailea, Maui.
498. ! 2016 Geoffrey Hartzler Interventional Cardiology Symposium. *The Surgical Turndown Patient*. July 11-13, 2016, Wailea, Maui.
499. ! ACC/SCAI Interventional Board Review 2016. *Medical Therapy vs Revascularization, Stable Angina and Acute Coronary Syndromes*. August 26, 2016, Amelia Island, FL.
500. ! ACC/SCAI Interventional Board Review 2016. *Post Percutaneous Coronary Intervention Management*. August 26, 2016, Amelia Island, FL.
501. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease*. October 30, 2016, Washington, DC.
502. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *When Bypass Grafts Fail*. October 30, 2016, Washington, DC.
503. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *Device Overview and Ongoing Study Design: Medtronic GLOBAL SYMPLICITY SPYRAL HTN*. October 30, 2016, Washington, DC.
504. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *Alcohol Chemical Neurolysis (Ablative Solutions): Peregrine Results and the Sham-controlled TARGET BP I Trial*. October 30, 2016, Washington, DC.
505. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *Chemical Neuromodulation as a Novel Approach to Renal Denervation: TARGET BP I Unique Drug/Device Combination Trial Design*. October 31, 2016, Washington, DC.
506. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *BioNir and Outcomes from Nireus Phase II and Bionics Pivotal Trials*. October 31, 2016, Washington, DC.
507. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *Micell Clinical Trials Program*. October 31, 2016, Washington, DC.
508. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *ACCEL Interview: BIONICS Clinical Trial Program*. October 31, 2016, Washington, DC.

509. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *The Closing Debate: Is PCI Now Standard of Care in Left Main Disease?* October 31, 2016, Washington, DC.
510. ! Transcatheter Therapeutics (TCT) 2016 Scientific Sessions. *Redefining DES: BIONICS and NIREUS*. November 1, 2016, Washington, DC.
511. International Conference for Innovations (ICI) 2016 Scientific Sessions. *BioNir Ridafirolimus Drug Eluting Stent Clinical Trial Program: the NIREUS and BIONICS Trials*. December 7, 2016, Tel Aviv, Israel.
512. ! Complex High Risk and Indicated Patients (CHIP) Step-By-Step Approach. *Left Main Revascularization, Step-By-Step*. January 21, 2017, Boca Raton, FL.
513. SIRIUS Radio, January 25, 2017. *Heart to Heart with Dr. Fred Feit*.
514. ! Peninsula Health 20th Annual Coastal Cardiac and Vascular Conference. *Bioresorbable Scaffold technologies for coronary revascularization*. February 18, 2017. Cambridge, Maryland.
515. ! CRT 2017. *Contemporary outcomes with CTO revascularization*. February 19, 2017. Washington, DC.
516. ! CRT 2017. *CTO revascularization, live case moderator*. February 19, 2017. Washington, DC.
517. ! CTO Summit. *CTO revascularization, live case moderator*. February 23, 2017. New York New York.
518. ! CTO Summit. *PERSPECTIVE Trial: Interim Results*. February 24, 2017. New York New York.
519. ! CTO Summit. *EXPERT CTO: 3-Year Outcomes*. February 24, 2017. New York New York.
520. ! American College of Cardiology Scientific Sessions. *Left main case presentation, CHIP program: Left Main PCI at the intersection of evidence and technique*. March 17, 2017. Washington, DC.
521. ! American College of Cardiology Scientific Sessions. *Three-Year Outcomes in 'Real-World' Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent in the PROMUS Element Plus U.S. Post-Approval Study (PE-Plus PAS)*. March 18, 2017. Washington, DC.
522. ! American College of Cardiology Scientific Sessions. *Moderator, live case presentations*. March 18, 2017. Washington, DC.
523. ! American College of Cardiology Scientific Sessions. *Discussant, late breaking clinical trials*. March 18, 2017. Washington, DC.
524. ! American College of Cardiology Scientific Sessions. *Avoiding lifelong treatment: is mechanical treatment of blood pressure still a possibility?* March 19, 2017. Washington, DC.
525. ! University of Pittsburgh 3rd Annual Transradial and Complex Cardiac Interventional Symposium. *Complications associated with transradial catheterization*. March 24, 2017. Pittsburgh, PA.
526. ! University of Pittsburgh 3rd Annual Transradial and Complex Cardiac Interventional Symposium. *An Evidence and Practice-Based Rationale for Transradial Complex Coronary Intervention*. March 24, 2017. Pittsburgh, PA.
527. ! China Interventional Therapeutics 2017. *Perspectives on Percutaneous Circulatory Support: An Intra-aortic Balloon Pump is Not Enough for Many Patients*. March 31, 2017. Beijing, China.
528. ! China Interventional Therapeutics 2017. *Status of Current Generation Durable Polymer DES: Efficacy and Safety Proven*. April 1, 2017. Beijing, China.

529. ! China Interventional Therapeutics 2017. *Renal Denervation Update: What We Know and What We Have Learned*. April 1, 2017. Beijing, China.
530. ! China Interventional Therapeutics 2017. *Complex PCI Live Case Operator, Anzhen Hospital*. April 1, 2017. Beijing, China.
531. ! Latin American Technology Exchange Program. *Chronic total occlusion revascularization 2017*. April 5, 2017. Panama City, Panama.
532. ! Latin American Technology Exchange Program. *Renal denervation next steps: evidence and future directions*. April 6, 2017. Panama City, Panama.
533. ! Latin American Technology Exchange Program. *DAPT pharmacology: clinical trials and therapeutic recommendations*. April 6, 2017. Panama City, Panama.
534. ! 23rd Annual Fellows' Course 2017. *Catheter-based circulatory support. Opportunities for indication expansion and technology development*. April 8, 2017. Orlando, FL.
535. ! 23rd Annual Fellows' Course 2017. *Evolution of left main percutaneous revascularization*. April 8, 2017. Orlando, FL.
536. ! SCAI 2017. *Economics of CTO revascularization*. May 12, 2017. New Orleans, LA.
537. ! SCAI 2017. *Tryton technology for coronary bifurcation disease*. May 12, 2017. New Orleans, LA.
538. EuroPCR 2017. *The EluNIR drug eluting stent clinical trial program*. May 17, 2017. Louis Vuitton Foundation, Paris, France.
539. ! Geoffrey O. Hartzler Interventional Cardiology Symposium. *The EluNIR drug-eluting stent clinical trial program*. July 17, 2017. Maui, Hawaii.
540. ! Geoffrey O. Hartzler Interventional Cardiology Symposium. *Is there compelling evidence that CTO recanalization improves clinical outcomes?* July 18, 2017. Maui, Hawaii.
541. ! Geoffrey O. Hartzler Interventional Cardiology Symposium. *EXPLORE, DECISION CTO, EURO CTO: Critical Appraisals*. July 18, 2017. Maui, Hawaii.
542. ! Geoffrey O. Hartzler Interventional Cardiology Symposium. *The Surgical Turndown Patient. Opportunities for Those with Limited Options*. July 19, 2017. Maui, Hawaii.
543. ! Geoffrey O. Hartzler Interventional Cardiology Symposium. *Renal Denervation. Really? Really!* July 19, 2017. Maui, Hawaii.
544. ! European Society of Cardiology Scientific Sessions. *Late Breaking Clinical Trial: Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial*. August 26, 2017, Barcelona, Spain.
545. ! European Society of Cardiology Scientific Sessions. *Post Myocardial Infarction Risk for Sudden Cardiac Death: Incidence, Predictors and Strategy to Reduce Risk*. August 28, 2017, Barcelona, Spain.
546. ! www.theheart.org. *Renal denervation: risen from the ashes*. August 28, 2017, Barcelona, Spain.
547. ! Transcatheter Therapeutics (TCT) 2017. *Tryton Bifurcation Technology: Present State and Future Directions*. October 30, 2017. Denver, Colorado.
548. ! Transcatheter Therapeutics (TCT) 2017. *PERSPECTIVE Trial: Procedural, Clinical and Health Status Outcomes Among Patients Undergoing Chronic Total Occlusion Percutaneous Revascularization*. October 30, 2017. Denver, Colorado.

549. ! Transcatheter Therapeutics (TCT) 2017. *Safety and Effectiveness of XIENCE Stents in Chronic Total Occlusions Revascularization: Long-term Results from the EXPERT CTO Multicenter Trial*. October 30, 2017. Denver, Colorado.
550. ! Transcatheter Therapeutics (TCT) 2017. *The EluNIR Clinical Trial Program: BIONICS and NIREUS Clinical Trials*. October 30, 2017. Denver, Colorado.
551. ! Transcatheter Therapeutics (TCT) 2017. *Provisional versus Planned Two-Stent Technique in Patients with Distal Bifurcation Left Main Disease Undergoing PCI: the EXCEL Trial*. October 31, 2017. Denver, Colorado.
552. ! Transcatheter Therapeutics (TCT) 2017. *Procedural Strategy and Clinical Outcomes in Patients Undergoing PCI for Left Main Trifurcation Disease: the EXCEL Trial*. October 31, 2017. Denver, Colorado.
553. ! Transcatheter Therapeutics (TCT) 2017. *Trial Considerations for Percutaneous Mechanical Support Devices: Necessity, Challenges and Lessons Learned*. October 31, 2017. Denver, Colorado.
554. ! Interface in Interventional Cardiology: An SCAI India Initiative. *Complicated complications*. December 16, 2017. Mumbai, India.
555. ! Interface in Interventional Cardiology: An SCAI India Initiative. *Complex chronic total occlusion revascularization*. December 17, 2017. Mumbai, India.
556. ! Interface in Interventional Cardiology: An SCAI India Initiative. *Drug-eluting stents and scaffolding: advancing standards of care and comparison*. December 17, 2017. Mumbai, India.
557. ! Onyx ONE Global Clinical Trial Program Investigator Meeting. *DAPT Duration Following PCI: The Intersection of Art and Science in Clinical Practice*. February 2, 2018. Hong Kong, China.
558. ! Chronic Total Occlusion Summit 2018. *CTO Evidence: An Interventionalist's Perspective*. February 16, 2018. New York, New York.
559. ! Chronic Total Occlusion Summit 2018. *Procedural Outcomes in Contemporary CTO PCI: Expectations and Aspirations*. February 16, 2018. New York, New York.
560. ! 22nd Annual Coastal Cardiac and Vascular Conference. February 17, 2018. *Renal Denervation Next Steps: Evolution of Evidence and Future Directions*. Cambridge, Maryland.
561. ! CRT 2018. *The EluNIR Clinical Trials Program*. March 5, 2018. Washington, DC.
562. ! CRT 2018. *Late Breaking Clinical Trials. BIONICS Trial 2-year clinical outcomes*. March 5, 2018. Washington, DC.
563. ! SCAI 2018. *SCAI TV: Short-term Dual Antiplatelet Therapy*. April 26, 2018. San Diego, CA.
564. ! SCAI 2018. *Late Breaking Clinical Trials. PERSPECTIVE: Procedural, in-hospital, and long-term outcomes for chronic total coronary occlusion revascularization with the Resolute zotarolimus-eluting stent*. April 26, 2018. San Diego, CA.
565. ! SCAI 2018. *SPYRAL HTN Program. Latest evidence and global clinical trial update*. April 26, 2018. San Diego, CA.
566. ! SCAI 2018. *Late Breaking Clinical Trials. Ultrathin sirolimus-eluting bioresorbable polymer DES as a standard of care and comparison*. April 26, 2018. San Diego, CA.
567. ! TCT Asia Pacific. April 29, 2018. *Contemporary drug-eluting stent evolution: dedication for advancement*. Seoul, Korea.

568. ! TCT Asia Pacific. April 29, 2018. *Complex coronary interventional programs: dedication for advancement*. Seoul, Korea.
569. ! TCT Asia Pacific. April 29, 2018. *Ultrathin sirolimus-eluting bioresorbable polymer DES as a standard of care and comparison*. Seoul, Korea.
570. ! TCT Asia Pacific. April 29, 2018. *Left main revascularization strategies and outcomes: insights from contemporary trials*. Seoul, Korea.
571. ! EuroPCR 2018. May 23, 2018. *Late-Breaking Clinical Trials. Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-Controlled SPYRAL HTN ON MED Trial*. Paris, France.
572. ! EuroPCR 2018. May 24, 2018. *SPYRAL HTN ON MED Trial: Trialist's Perspective*. Paris, France.
573. ! EuroPCR 2018. May 24, 2018. *Optimizing outcomes in complex coronary disease with ultrathin bioresorbable polymer DES*. Paris, France.
574. ! EuroPCR 2018. May 25, 2018. *EluNIR Ridafirolimus Eluting Coronary Stent System and Clinical Trials Program*. Paris, France.